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ABSTRACT 
 
Laura Ann Tollini: EXPLORING THE IN VIVO ROLE OF THE MDM2 RING FINGER DOMAIN 
IN P53 REGULATION 
(Under the direction of Yanping Zhang) 
 
Classically characterized as an “overarching” tumor suppressor, p53 is frequently found mutated, 
deleted, or misregulated in human cancers.  Through its role as a transcription factor, p53 is 
capable of influencing the transcription of a number of genes critical in cell cycle arrest, 
senescence, apoptosis, and cellular metabolism. Mdm2 is widely accepted as the primary 
negative regulator of p53; canonically, Mdm2 is thought to regulate p53 through two 
mechanisms; 1) directly binding the p53 transactivation domain, suppressing p53 activity, and 2) 
functioning as an E3 ubiquitin ligase capable of ubiquitinating p53, targeting it for nuclear export 
and degradation by the proteasome. MdmX, a homologue and binding partner of Mdm2, is also 
capable of regulating p53 activity through directly binding to the p53 transactivation domain, 
however, MdmX does not demonstrate intrinsic E3 ligase activity.  Both Mdm2:MdmX binding 
and Mdm2 E3 ligase function are conferred by the Mdm2 RING finger domain.  To better 
understand the role of the Mdm2 RING finger domain in p53 regulation in vivo, we have 
generated a knock-in mouse model harboring a Tyr-to-Ala substitution at the 487 amino acid 
residue of murine Mdm2, Mdm2Y487A, which inactivates Mdm2 E3 ligase function without 
affecting its ability to bind with MdmX, effectively separating these two Mdm2 RING finger 
domain functions. Unexpectedly, Mdm2Y487A/Y487A mice were viable and developed normally into 
adulthood. While disruption of Mdm2 E3 ligase function by the Mdm2Y487A mutation resulted in 
p53 accumulation, p53 transcriptional activity remained low under basal conditions; however, 
exposure to even low levels of stress resulted in hyperactive p53, and p53-dependent mortality 
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in Mdm2Y487A/Y487A mice. Disruption of Mdm2-mediated degradation of p53 serves as the 
underpinning of many cancer treatments aimed at reactivation of p53, but as observed in our 
Mdm2Y487A knock-in mouse, inactivation of Mdm2 E3 ubiquitin ligase function without obliterating 
Mdm2:MdmX interaction does not efficiently activate p53; however, disruption of Mdm2 E3 
ligase function can increase sensitivity to irradiation induced DNA damage and lethality. This 
study provides further insight into the Mdm2-p53 autoregulatory loop and sheds new light on 
current issues surrounding the development of effective therapeutics targeting the p53 pathway. 
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1. CHAPTER 1: INTRODUCTION1 
Discovery and Overview of p53 
Now widely accepted as a key tumor suppressor gene and protein product, p53 was 
originally identified as a binding partner of SV40, and initially proposed to function as an 
oncogene (DeLeo et al., 1979; Kress et al., 1979; Lane and Crawford, 1979; Linzer and Levine, 
1979; Melero et al., 1979; Smith et al., 1979).  However, sequencing of the p53 cDNA clones 
used in these early studies revealed that the oncogenic functions of p53 were the result of the 
study of mutant, rather than wild type p53 cDNA clones (Levine and Oren, 2009). Following this 
discovery, the completion of assays using truly wild type p53 made clear that in stark contrast 
with original observations, p53 has many properties of a tumor suppressor.  
While wild-type p53 does not promote tumor development and growth, mutation or 
depletion of p53 is associated with the transforming activities observed in a number of tumor 
derived cell lines from both mouse and human lineages (Baker et al., 1989; Eliyahu et al., 1988; 
Finlay et al., 1988; Halevy et al., 1991). Furthermore, individuals suffering from Li-Fraumeni 
syndrome, characterized by an autosomal dominant p53 loss-of-function allele, present with 
increased susceptibility to a number of cancers including breast, osteosarcoma, soft tissue 
sarcoma, as well as many others (Malkin et al., 1990; Srivastava et al., 1990). Although Li-
Fraumini syndrome remains a rare genetic disease, it clearly demonstrates a correlation 
between mutations in TP53 and an increased risk for the development of a number of cancers 
beginning in childhood.  The development and characterization of a p53-/- knockout mouse 
                                               
1The subsection of this chapter entitled “In Vivo Study of the p53 Regulatory Pathway” is 
adapted from a review article previously published in Genes & Cancer. The original citation is as 
follows: Tollini, L. A., and Zhang, Y. (2012). p53 Regulation Goes Live-Mdm2 and MdmX Co-
Star: Lessons Learned from Mouse Modeling. Genes Cancer 3, 219-225. 
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model allowed for further study and characterization of the effect of loss of p53 in mammals; in 
the mouse, loss of p53 did not affect development, but it demonstrated a highly penetrant 
correlation to increased incidence of tumors, specifically lymphomas (Donehower et al., 1992). 
Together, these observations contributed to the characterization of p53 as a bona fide tumor 
suppressor.  
 
Function of p53  
p53 functions as a tumor suppressor primarily through its ability to act as a transcription 
factor for a number of genes essential for cell cycle arrest, senescence, and apoptosis; for a 
large number of these target genes p53 regulates transcription through direct, sequence specific 
DNA binding via its central DNA binding domain (Riley et al., 2008) (Figure 1-1).  In addition to 
the DNA binding domain, the N-terminal transactivation domain of p53, which serves as a 
binding domain for a number of proteins, including key transcriptional co-activators, is also 
important in its activity as a transcription factor (Soussi and May, 1996). Tight protein-protein 
binding allows for p53 to recruit transcription proteins, such as TATA-binding protein-associated 
factors (TAFs) and a number of histone acetyltransferases, to the promoter enhancer region of 
its target genes to induce transcription, and increase transcriptional activity (Farmer et al., 1996; 
Gu and Roeder, 1997; Gu et al., 1997; Thut et al., 1995). Recruitment of histone 
acetyltransferases to the promoter enhancer region of these target genes contributes to 
enhanced transcriptional activity by increasing acetylation of histone lysine residues, which 
subsequently results in a more accessible chromatin conformation (Gu and Roeder, 1997; Gu et 
al., 1997). In addition to promoting the transcription of its target genes, p53 is also capable of 
repressing target gene transcription through a few mechanisms, including binding-site overlap, 
squelching of transcriptional activators, and recruitment of histone deacetylases (HDACs); it 
remains unclear what distinguishes the RE of a gene activated by p53 from that of one that is 
repressed by p53 (Riley et al., 2008).  
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The list of genes directly or indirectly regulated by p53 continues to grow, with more than 
150 genes currently identified; described below are a few examples of well characterized p53 
target genes that play a key role in its tumor suppressor capabilities (el-Deiry, 1998; Riley et al., 
2008; Vogelstein et al., 2000; Zhao et al., 2000). CDKN1A codes for the cell cycle regulator 
p21WAF1/CIP1 (p21 hereafter), and is transcriptionally upregulated by p53; increased levels of p21 
result in inhibition of both the G1–to-S and G2-to-mitosis transition in the cell cycle, or more 
simply, cell cycle arrest (el-Deiry et al., 1995; Saramaki et al., 2006). p53 can also promote 
apoptosis as mediated through the transactivation of a number of pro-apoptotic genes such as 
Bax, PUMA, and NOXA. Following transactivation by p53, Bax, a Bcl-2 family member protein, 
promotes apoptosis through induction of the mitochondrial permeability transition (Pastorino et 
al., 1998); in a related role, direct activation of PUMA by p53 promotes apoptosis through 
affecting the subcellular localization of Bax (Zhang et al., 2009). NOXA, another member of the 
Bcl-2 protein family, facilitates apoptosis following transcriptional upregulation by p53 through its 
interaction with anti-apoptotic Bcl-2 family proteins and activation of caspase-9 (Oda et al., 2000; 
Villunger et al., 2003). Additionally, p53 activity can promote DNA damage repair; p53 
transactivation of GADD45α results in increased binding between GADD45α and PCNA, which 
then inhibits entry into S phase of the cell cycle, and stimulates DNA excision repair (Smith et al., 
1994). 
While many of the transcriptional targets of p53 contribute to its role as a tumor 
suppressor through promoting cell cycle arrest, senescence, and apoptosis, p53 levels also 
directly affect levels of leukemia inhibitory factor (LIF), an essential component in mammalian 
reproduction for proper implantation of the blastocyst (Hu et al., 2007; Levine et al., 2011; 
Stewart et al., 1992).  LIF levels increase significantly at the time of implantation in a p53 
dependent manner; in the absence of p53, as in  p53-/- mice, LIF is not increased and 
subsequently the frequency of embryo implantation is significantly reduced (Hu et al., 2007).  
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The effect of p53 levels on reproduction via LIF demonstrates a role for p53 in normal cellular 
processes, outside of the stress response.     
   
Regulation of p53 
Generally, p53 levels and activity are kept relatively low and it is only upon activation, 
which can occur in response to a wide variety of stimuli, including DNA damage, oncogene 
activation, hypoxia, and ribosomal stress, that p53 becomes activated as a transcription factor 
(Levine and Oren, 2009). It remains poorly understood how p53 detects and differentiates 
between the stressors responsible for its activation, and furthermore, what determines which of 
the numerous p53 transcriptional target genes are activated or repressed in response.  
p53 regulation, in large part, hinges on its interaction with the E3 ubiquitin ligase Mdm2. 
Mdm2 is a member of the RING family of E3 ubiquitin ligases and functions to ubiquitinate p53; 
through forming a scaffold between p53 and E2 ubiquitin conjugating enzymes, Mdm2 facilitates 
the transfer of ubiquitin from the E2 to lysine residues of its target substrate, p53 (Metzger et al., 
2012). Ubiquitination of p53 results in its export from the nucleus to the cytoplasm, followed by 
degradation by the 26 S proteasome (Michael and Oren, 2003). In vivo, the absence of Mdm2 
results in p53-dependent early embryonic lethality (described further in Chapter 1: In vivo study 
of the p53 regulatory pathway)(Jones et al., 1995; Montes de Oca Luna et al., 1995), however 
p53 degradation dynamics in the absence of Mdm2 were able to be studied through the use of 
an inducible p53 fusion protein, p53ERTAM (p53ER hereafter) (Ringshausen et al., 2006).  
Induction of p53 in Mdm2-/-; p53ER/-  mice results in significant p53 activity which correlates with 
lethal pathologies, further implicating the critical role of Mdm2 in p53 regulation; however, p53ER 
degradation is still observed in the absence of Mdm2, suggesting that Mdm2-independent 
mechanisms for p53 degradation exist (Ringshausen et al., 2006). In fact, a number of 
alternative E3 ubiquitin ligases demonstrating specificity for p53 have been identified such as 
Pirh2 (Leng et al., 2003), COP1(Dornan et al., 2004), and TOPORS (Rajendra et al., 2004), 
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however, genetic evidence supports the reigning importance of Mdm2 E3 ubiquitin ligase 
activity in regulating p53 stability (Lee and Gu, 2010). It is widely accepted that low basal levels 
of p53 are maintained primarily through post-translational modifications, specifically relying on 
Mdm2-mediated ubiquitination to promote p53 degradation.  
In addition to ubiquitination, other post-translational modifications to p53, including 
phosphorylation and acetylation, influence p53 stability and activity, often through direct or 
indirect interference of p53:Mdm2 interaction. In response to DNA damage, p53 is 
phosphorylated, which results in dissociation from Mdm2, and with that, stabilization (Shieh et 
al., 1997). The protein kinases ATM and ATR directly promote the phosphorylation of p53 
through their own kinase activity, as well as indirectly through phosphorylation of the serine-
threonine checkpoint effector kinases Chk2 and Chk1, respectively; phosphorylation activates 
Chk2 and Chk1, which then phosphorylate Ser20 of p53, increasing p53 stabilization (Chehab 
et al., 2000; Chehab et al., 1999; Shieh et al., 2000; Smith et al., 2010). The ATM-Chk2 and 
ATR-Chk1 kinase pathways uniquely mediate p53 phosphorylation dependent on the type of 
stimuli; in response to ionizing irradiation, ATM is the primary kinase for phosphorylation, 
specifically phosphorylating Ser9, Ser15, and Ser46 of human p53 (Banin et al., 1998; Canman 
et al., 1998; Saito et al., 2002), while in response to UV irradiation, ATR functions as the primary 
kinase, phosphorylating p53 at Ser15 and Ser37 (Tibbetts et al., 1999).  
As mentioned above, histone acetyltransferases, specifically CBP/p300 and PCAF, 
enhance p53 activity through functioning as co-activators for p53; direct binding of p300 to the 
transactivation domain of p53 increases p53 transcriptional activity (Figure 1-1) (Avantaggiati et 
al., 1997; Dornan et al., 2003; Lill et al., 1997; Teufel et al., 2007). Along with serving as co-
activators for p53 activity, CBP/p300 and PCAF acetylate p53 itself. CBP/p300 specifically 
acetylates human p53 at Lys 372, Lys 373, Lys 381, and Lys 382, and PCAF acetylates p53 at 
Lys 320 (Liu et al., 1999; Sakaguchi et al., 1998). Treatment with deacetylase inhibitors such as 
Trichostatin A (TSA) results in increased levels of acetylated p53 in vivo, implicating a role for 
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deacetylation in the regulation of p53 acetylation (Sakaguchi et al., 1998). Providing additional 
support for the functional significance of deacetylation in p53 regulation, interaction of p53 with 
PID, a component of the NuRD complex, facilitates histone deacetylase (HDAC) activity, and 
with that reduces p53 activity (Juan et al., 2000; Luo et al., 2000). Furthermore, overexpression 
of PID correlates with increased cell growth, and decreased apoptosis, indicating a correlation 
between increased deacetylase activity and reduced p53 activity in vivo (Luo et al., 2000). While 
it is yet to be explicitly determined how p53 acetylation regulates p53 activity mechanistically, 
Lys-to-Arg substitutions at three well characterized p53 acetylation residues abolishes the ability 
of p53 to activate p21 or PUMA in vivo, elegantly demonstrating genetically the importance of 
p53 acetylation for specific p53 activity (Li et al., 2012; Prives and Manley, 2001).   
 
Mdm2 and MdmX: Essential Regulators of p53 
Discovery and Overview of Mdm2 
Mouse double minute 2 (Mdm2) was so named because of its discovery as an amplified 
DNA sequence in the form of small, acentromeric, extrachromosomal nuclear bodies termed 
double minutes in the spontaneously transformed 3T3DM mouse tumor cell line (Cahilly-Snyder 
et al., 1987). The newly identified Mdm2 was found to be amplified more than 50 fold in 3T3DM 
cells, and capable of inducing tumorigenic transformation in NIH3T3 cells (Cahilly-Snyder et al., 
1987; Fakharzadeh et al., 1991). Shortly following its discovery, Mdm2 was identified as a 
binding partner of p53, capable of inhibiting p53 activity, and today it is widely accepted as the 
primary negative regulator of p53 (Bond et al., 2005; Momand et al., 2000; Momand et al., 1992; 
Wade et al., 2010).  
Mdm2 functions to regulate p53 stability and activity through two distinct mechanisms 
(Figure 1-2). First, through its N-terminus p53 binding domain Mdm2 binds to the p53 
transactivation domain, effectively inhibiting p53 activity as a transcription factor (Momand et al., 
1992; Oliner et al., 1993; Thut et al., 1997). Coupled with its inhibition of p53 activity through 
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direct binding, Mdm2 is also capable of regulating p53 stability via its function as an E3 ubiquitin 
ligase. The RING finger domain of Mdm2 confers E3 ubiquitin ligase activity, providing for 
Mdm2-mediated ubiquitination of p53, which targets p53 for export from the nucleus and 
subsequent degradation by the proteasome (Haupt et al., 1997; Honda et al., 1997; Kubbutat et 
al., 1997).   
In addition to facilitating the transcription of genes essential for its tumor suppressor 
function, p53 also promotes the transcription of Mdm2, effectively forming an autoregulatory 
feedback loop (Barak et al., 1993; Perry et al., 1993). Transcription of the Mdm2 gene is 
dictated by an upstream constitutive promoter, P1, and an internal P2 promoter located near the 
end of the first intron. While the Mdm2 P1 locus allows for p53-independent transcription, p53 
contributes significantly to Mdm2 levels through its promotion of transcription at the Mdm2 P2 
promoter (Barak et al., 1994). Mdm2 stability is also regulated at the post-translational level. 
Similar to its ability to ubiquitinate p53, in vitro, Mdm2 has been demonstrated to 
autoubiquitinate to promote its own degradation (Fang et al., 2000; Honda and Yasuda, 2000). 
The development of a knock-in mouse model with ablated Mdm2 E3 ligase activity allowed for 
the study of Mdm2 degradation dynamics in vivo, and revealed that in the absence of intrinsic 
Mdm2 E3 ligase activity, degradation of Mdm2 itself is not disrupted (Itahana et al., 2007). The 
proteasome-dependent degradation of Mdm2 observed even in the absence of Mdm2 E3 
ubiquitin ligase activity in vivo suggests that degradation of Mdm2 is not dependent upon 
autoubiquitination, and points to the likelihood that an alternative E3 ligase is functioning to 
ubiquitinate Mdm2 (Clegg et al., 2008; Itahana et al., 2007). The identification of an E3 ligase 
with specificity for Mdm2 remains a key aspect of Mdm2 regulation to be further explored. 
Mdm2 regulation of p53 can be mediated through a number of different mechanisms, 
including changes in Mdm2 stability as described above, protein-protein interactions, and post-
translational modifications. p14ARF/p19ARF (ARF hereafter), a nucleolar tumor suppressor protein, 
can antagonize Mdm2 downregulation of p53 in part through its ability to bind Mdm2 and 
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sequester it to the nucleolus (Tao and Levine, 1999; Weber et al., 1999). Additionally, ARF is 
observed to form a ternary complex with Mdm2 and p53, which prevents nuclear export of both 
proteins, and with that enhances p53 stability and activity (Kamijo et al., 1998; Pomerantz et al., 
1998; Stott et al., 1998; Zhang and Xiong, 1999; Zhang et al., 1998). A growing number of 
ribosomal proteins, including RL5 (Dai and Lu, 2004; Marechal et al., 1994), RL11 (Lohrum et 
al., 2003; Zhang et al., 2003), and RL23 (Dai et al., 2004; Jin et al., 2004), along with many 
others, are also capable of antagonizing Mdm2 regulation of p53 through binding to the central 
domain of Mdm2 (Figure 1-1). Interaction between Mdm2 and these ribosomal proteins, as often 
occurs in response to ribosomal stress, results in disruption of Mdm2:p53 interaction and 
increased stability and activity of p53.  
 
Mdm2:MdmX Heterodimerization in p53 Regulation 
The RING finger domain of Mdm2 not only confers its E3 ubiquitin ligase function, but it 
is also through this domain that Mdm2 is able to dimerize with the RING domain of the 
homologous protein MdmX. Similar to Mdm2, MdmX is an oncogenic protein capable of 
promoting aberrant cell growth and immortalization, largely through antagonism of p53 function 
(Danovi et al., 2004; Lenos et al., 2011). Through its N-terminal p53 binding domain, MdmX 
directly binds the p53 transactivation domain, and through this function MdmX can suppress 
p53 transcriptional activity (Shvarts et al., 1996). While the RING finger domain of MdmX is 
structurally similar to that of Mdm2, MdmX does not harbor any intrinsic E3 ubiquitin ligase 
activity (Jackson and Berberich, 2000; Poyurovsky et al., 2007). MdmX is a relatively stable, 
ubiquitously expressed protein, but following DNA damage Mdm2 can ubiquitinate MdmX to 
promote its degradation (de Graaf et al., 2003; Kawai et al., 2003; Linke et al., 2008; Pan and 
Chen, 2003). 
Heterodimerization of Mdm2 and MdmX influences the stabilization of each of these 
proteins, as well as the stability and activity of p53 directly through ubiquitination, as well as 
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through additional less well-understood mechanisms. While Mdm2 is capable of forming 
homodimers, a number of studies have demonstrated that Mdm2:MdmX heterodimers form 
preferentially and result in a more stable structure (Linke et al., 2008; Tanimura et al., 1999). 
Heterodimerization promotes Mdm2 stability, which in turn correlates with enhanced 
degradation of p53 (Stad et al., 2001). Although MdmX lacks intrinsic E3 ubiquitin ligase activity, 
interaction between Mdm2 and MdmX is demonstrated to enhance the E3 ubiquitin ligase 
activity of wild-type Mdm2, and restore E3 ligase activity in mutated Mdm2 (Singh et al., 2007; 
Uldrijan et al., 2007). Mdm2:MdmX heterodimerization is also proposed to be important for 
subcellular localization of MdmX; unlike Mdm2, MdmX lacks a nuclear localization and nuclear 
export signal domain and as a result interaction with Mdm2 or p53 is necessary for nucleo-
cytoplasmic shuttling of MdmX (Li et al., 2002; Marine and Jochemsen, 2005).  
Posttranslational modifications play a large role not only in Mdm2 and MdmX 
stabilization, as dictated by ubiquitination, but also through changes in localization and binding 
dynamics. Phosphorylation of both Mdm2 and MdmX serves to differentially moderate p53 
activity in response to stress. Through affecting subcellular localization and nucleo-cytoplasmic 
shuttling, phosphorylation of various residues of the Mdm2 protein can function to enhance or 
disrupt p53 activity. Phosphorylation of human Mdm2 at Ser166 and Ser186 by the 
phosphokinase AKT promotes the translocation of Mdm2 from the cytoplasm into the nucleus, 
inhibiting p53 and increasing cell growth and survival (Mayo and Donner, 2001). Conversely, the 
rapid phosphorylation of Mdm2 at Ser395 by ATM disrupts nucleo-cytoplasmic shuttling of p53, 
promoting p53 stabilization and increased p53 activity (Maya et al., 2001). In response to a 
number of DNA damaging reagents, but not ribosomal stress, ATM also facilitates the 
phosphorylation of Mdm2 at Ser386 and Ser429 (Cheng et al., 2009). Phosphorylation of Mdm2 
at Ser386, Ser395, and Ser429, singly or in combination, disrupts oligomerization of Mdm2 via 
its RING finger domain and correlates with stabilization of p53; disruption of Mdm2 
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oligomerization is proposed to prevent the formation of the necessary scaffolding for ubiquitin 
chain formation (Cheng et al., 2009).    
The phosphokinases AKT and ATM serve to modulate phosphorylation of MdmX, as well 
as Mdm2. AKT-mediated phosphorylation of human MdmX at Ser367 results in the generation 
of a 14-3-3 phospho-dependent binding site. Interaction with 14-3-3, a small acidic protein, 
promotes the stabilization of MdmX, which in turn stabilizes Mdm2, decreasing p53 
transcriptional activity (Lopez-Pajares et al., 2008). Phosphorylation of MdmX can also 
contribute to the protein stability of MdmX itself; phosphorylation of a number of residues near 
the RING domain of MdmX by the ATM-Chk2 kinase pathway, enhances Mdm2 binding affinity 
for MdmX, promoting MdmX ubiquitination and degradation after DNA damage (Chen et al., 
2005) While much remains to be explored to provide a comprehensive understanding of the 
precise mechanisms through which phosphorylation of Mdm2 and MdmX functions to mediate 
the p53 regulatory pathway, significant data draws a correlation between the phospho-status of 
these proteins and p53 activity, as determined by cell cycle arrest and transcriptional activity of 
p53 target genes, in response to DNA damage (Cheng et al., 2009; Lopez-Pajares et al., 2008; 
Maya et al., 2001). The intricate coordination of post-translational modifications to Mdm2 and 
MdmX serves to add another level of differential control to p53 regulation.  
 
In vivo Study of the p53 Regulatory Pathway  
It has been over 30 years since p53 was first identified, and over the course of those 30 
years, our knowledge of the breadth and importance of p53 function has continued to grow. Due 
to its role as a transcription factor for a number of downstream target genes important in cell 
cycle arrest, apoptosis, and senescence, as well as the fact that p53 is deleted, mutated, or 
misregulated in a majority of cancers, p53 is now well characterized as a key tumor suppressor 
gene (Danovi et al., 2004; Hainaut et al., 1997; Levine, 1997; Momand et al., 1998; Ramos et al., 
2001). In more recent years, the importance of p53 has been further expanded as it is now 
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implicated to have key roles in reproduction and metabolism in addition to its role as a tumor 
suppressor (Deisenroth and Zhang, 2011; Lane and Levine, 2010; Levine et al., 2011). With 
such a range of functions, as well as the strong correlation between disease and aberrant p53 
expression and function, a thorough understanding of p53 regulation is critical.  
Mdm2 was identified as a p53-interacting protein in the early 1990s and is now generally 
accepted to function as the primary negative regulator of p53 via its ability to act as an E3 
ubiquitin ligase for p53 as well as its ability to bind to the p53 transactivation site and inhibit p53 
activity (Lin et al., 1994; Momand et al., 1992; Wu et al., 1993; Yang et al., 2004). While 
additional E3s for p53, including Pirh2 (Leng et al., 2003), COP1(Dornan et al., 2004), and 
TOPORS (Rajendra et al., 2004), have been identified, Mdm2 appears to be irreplaceable in its 
role in controlling p53 stability. MdmX, a homolog of Mdm2, has also been revealed to be a key 
regulator of p53 (Shvarts et al., 1996). Similarly to Mdm2, MdmX is capable of binding to p53 via 
its N-terminus, inhibiting p53 activity (Shvarts et al., 1996). Although the RING finger domains of 
Mdm2 and MdmX share a high level of homology, MdmX does not function as an E3 ubiquitin 
ligase for p53 (Jackson and Berberich, 2000; Poyurovsky et al., 2007; Shvarts et al., 1996). 
While MdmX appears to play a unique and critical role in p53 regulation, it remains unclear 
exactly how and where MdmX is exerting this effect. Many of the strides that have been taken 
toward a better understanding of p53 regulation in vivo have been through the utilization of 
knock-out and knock-in mouse models. Despite the extensive study surrounding the function 
and regulation of p53, newly innovated mouse models continue to reveal that much remains 
unknown about how this critical gene and its protein product are regulated at physiological 
levels as well as the striking differences that can exist between in vitro and in vivo studies. While 
many questions remain, a focus on the use of in vivo models in p53 study is providing a clearer 
view of how this pathway is regulated, with a newfound emphasis on the role of the 
Mdm2:MdmX heterodimer. Here, we discuss the important role that mouse models have played 
in our current understanding of in vivo p53 regulation and how this valuable tool can be used to 
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further elucidate Mdm2:MdmX:p53 interactions, as well as speculate further on how Mdm2 and 
MdmX are functioning to regulate p53 when expressed at endogenous levels.  
 
Knock-Out Mouse Models: Setting the Stage 
Mdm2 is well characterized in vitro to regulate both p53 stability and activity, and through 
the development of an Mdm2 knock-out mouse model, it was made clear just how necessary 
Mdm2 is in this capacity. Deletion of the Mdm2 gene results in early embryonic lethality, most 
likely due to a failure to inhibit p53 function, as the timing of lethality in mutants coincides with 
an increase in the cell cycle in wild-type animals (Jones et al., 1995). The lethality of Mdm2 –/–
 mice is completely rescued with concomitant deletion of p53, which further suggests that Mdm2 
is necessary in a p53-dependent manner, specifically to downregulate p53 in embryogenesis 
(Jones et al., 1995; Montes de Oca Luna et al., 1995). In addition to demonstrating the 
necessity of Mdm2 in proper p53 regulation, the lethality of Mdm2–/– mice also served to 
demonstrate that too much, as well as too little, p53 activity can be detrimental. In a similar 
manner, knock-out of MdmX also results in p53-dependent early embryonic lethality (Parant et 
al., 2001). Despite the fact that MdmX is not historically thought to affect p53 stability as does 
Mdm2, deletion of MdmX results in activation of p53 and subsequent loss of cellular proliferation 
(Parant et al., 2001). The p53-dependent embryonic lethality of MdmX–/– mice implicates MdmX 
as a critical component in p53 regulation and suggests that, despite the similarities between 
Mdm2 and MdmX and how they interact with p53, these two proteins have non-redundant roles 
in p53 regulation in vivo. Haploinsufficiency yields divergent phenotypes for Mdm2 and MdmX, 
with MdmX+/– mice exhibiting increased radiosensitivity compared to Mdm2+/– mice and gender-
based differences in radiosensitivity existing in Mdm2+/– but not MdmX+/– mice, further 
emphasizing the potential for differing mechanisms of p53 regulation between the two proteins 
(Terzian et al., 2007). It has been hypothesized that Mdm2 and MdmX cannot compensate for 
one another because each protein serves a unique role in either the timing or mechanism of 
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regulation, but conclusive data supporting this hypothesis have yet to be shown (Marine et al., 
2006).  
 
Knock-In Mouse Models: Stealing the Spotlight 
The development of Mdm2 and MdmX knock-out models is invaluable in demonstrating 
the essential and nonredundant roles these 2 proteins play in p53 regulation, and while useful in 
identifying their general importance, the development of a number of Mdm2 and MdmX knock-in 
mouse models has allowed for a more focused look at the mechanisms through which Mdm2 
and MdmX are functioning to control p53. The RING finger domain of Mdm2 confers its ability to 
function as an E3 ubiquitin ligase for p53 (Honda et al., 1997). The introduction of a single point 
mutation in the RING finger domain, cysteine to alanine, at the 462–amino acid residue of 
Mdm2 (Mdm2C462A), disrupts Mdm2 E3 ubiquitin ligase activity (Itahana et al., 
2007). Homozygous mutation of Mdm2 in this manner results in embryonic lethality that, 
similarly to deletion of Mdm2, can be rescued with concomitant deletion of p53 (Itahana et al., 
2007). Despite leaving the p53-interacting N-terminus of Mdm2 intact and functional, the 
Mdm2C462A mutation leads to stabilization of p53 and p21, suggesting that Mdm2:p53 interaction 
in the absence of Mdm2 E3 ubiquitin ligase activity is not sufficient for proper regulation of p53 
activity (Itahana et al., 2007). While in vitro studies have shown that Mdm2 inhibits p53 by a 
dual mechanism involving both binding to p53 to inhibit its transcriptional activity and 
ubiquitinating p53 to target it for degradation, the lethality of the Mdm2 C462A/C462A knock-in mouse 
implicates the RING finger domain, presumably its E3 ubiquitin ligase activity, to be the critical 
mechanism through which Mdm2 is functioning. This finding highlights the importance of in 
vivo models in determining the true effect of regulatory mechanisms; while in vitro studies open 
the door to potential functions of different proteins and complexes, it is not until interactions are 
observed at physiological levels that the foundation for a true understanding of a protein’s 
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function can be laid; that is, just because a protein is capable of a specific function in vitro, this 
function will not necessarily be carried out in vivo at endogenous levels. 
In addition to disrupting Mdm2 E3 ubiquitin ligase activity, it was later found that the 
Mdm2C462A mutation also disrupts Mdm2:MdmX interaction (Clegg et al., 2012). Because of the 
fact that the Mdm2C462A mutation disrupts both E3 ubiquitin ligase activity as well as 
Mdm2:MdmX binding, from this model, it cannot be determined whether one or both of these 
RING finger domain functions is essential. The recent development of two MdmX mutant mouse 
models serves to address the significance and the potential function of Mdm2:MdmX interaction. 
Introduction of a cysteine-to-alanine point mutation at the 462–amino acid residue of MdmX 
(MdmXC462A) results in disruption of Mdm2:MdmX binding (Huang et al., 2011). Similarly, a 
second MdmX mutant lacking the RING domain, MdmXΔRING, also results in disruption of 
Mdm2:MdmX interaction (Pant et al., 2011). Because both MdmXC462A and MdmXΔRING maintain 
the ability to interact with p53 via the N-terminus, and as Mdm2 is left untouched and should be 
able to maintain its activity towards p53, these models allow for a closer look at whether Mdm2 
and MdmX work together or independently to regulate p53 and if it is necessary for the two 
proteins to interact with one another in order to function. Surprisingly, both MdmXC462A/C462A and 
MdmXΔRING/ΔRING homozygosity results in lethality by embryonic day 9.5 (Huang et al., 2011; Pant 
et al., 2011). These embryos demonstrate increased levels of a number of p53 downstream 
targets, including Mdm2, p21, Bax, and Puma, at both the transcriptional and protein levels, 
suggesting that disruption of the Mdm2:MdmX heterodimer allows for activation of p53 (Huang 
et al., 2011; Pant et al., 2011). Simultaneous deletion of p53 rescues the lethality observed in 
MdmXC462A and MdmXΔRING homozygotes, again suggesting that the lethality is due to 
overexpression and overactivity of p53 (Huang et al., 2011; Pant et al., 2011). Furthermore, the 
lethality of MdmXΔRING homozygotes is also rescued when the mutation is placed in the 
transcriptionally inactive p53515A/515A background as well as the transcriptionally hypomorphic 
p53Neo/Neo background, further supporting that the primary function of MdmX, at least during 
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embryonic development, is to restrain p53 (Pant et al., 2011). Of note, while the lethality 
observed in MdmXΔRING/ΔRING mice can be rescued by being placed in a p53Neo/Neo background, 
which expresses approximately 15% of wild-type p53 levels, Mdm2 knock-out mice are not 
similarly rescued, suggesting a difference in the mechanism and/or severity of p53 
misregulation between Mdm2–/– and MdmXΔRING/ΔRING mice (Wang et al., 2011a). While the 
lethality of these MdmX RING finger mutants is indicative of a critical role for the Mdm2:MdmX 
heterodimer in p53 regulation, the ability of reduced p53 expression to rescue MdmXΔRING/ΔRING, 
but not Mdm2–/–, lethality suggests that an additional level of regulation is likely at play. 
Moreover, embryonic lethality indicates only that heterodimerization plays a role in p53 
regulation during embryogenesis but not necessarily during later stages of development. 
Induction of the MdmXΔRING mutation in adult conditional Mdm4flxRING/ΔRING;CreER mice with 
tamoxifen resulted in viable animals, with only a slight upregulation of the p53 target, p21, and 
no change in Mdm2 or PUMA mRNA levels (Pant et al., 2011). The viability of adult mice with 
the MdmXΔRING mutation suggests that heterodimerization is not essential for p53 regulation in 
adult animals and that differing mechanisms likely exist to regulate p53 in embryogenesis and 
later in life. 
 
Mdm2:MdmX Heterodimerization: A Rising Star 
The combined pool of data from the knock-out and knock-in mouse models points to the 
Mdm2:MdmX heterodimer as a critical bastion of p53 regulation. While this idea is not new, 
through the characterization of these mouse models, it has been made clear that in vivo 
Mdm2:MdmX interaction plays a critical role in proper control of p53 stability and activity. The 
development of each of these mouse models has allowed for a more complete picture to 
emerge, and combined analysis of these models may allow for a deeper understanding of p53 
regulation in vivo and how the Mdm2:MdmX heterodimer may be functioning at the crux of this 
pathway (Figure 1-3). One tempting hypothesis is that heterodimerization affects the physical 
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structure of the complex and with that affects its affinity toward p53. In vitro, Mdm2 and MdmX 
form a tight 1:1 complex via their respective C-terminal RING finger domains, and further, 
heterodimers form preferentially to Mdm2:Mdm2 or MdmX:MdmX homodimers (Kostic et al., 
2006; Tanimura et al., 1999). In light of the homology that exists between Mdm2 and MdmX, it is 
unclear why heterodimers and homodimers cannot function interchangeably, but some evidence 
suggests that structural differences may exist in the RING finger of the Mdm2:MdmX 
heterodimer compared to the Mdm2 monomers of a homodimer (Linke et al., 2008). It is 
possible that the slight structural differences that exist in Mdm2:MdmX heterodimers affect the 
binding affinity of these proteins toward p53; however, problems with solubility and stability 
make it difficult to address this possibility directly through crystal structuring (Linke et al., 
2008). In mouse embryonic fibroblasts (MEFs), however, no difference is observed between the 
binding affinity of wild-type MdmX and MdmXC462A, which lacks heterodimerization, with p53 
(Huang et al., 2011). While it does not appear as if loss of heterodimerization affects p53:MdmX 
binding in MEFs, it is still possible that it exerts an effect on p53:Mdm2 binding. 
A second functional role for heterodimerization may be regulation of the subcellular 
localization of MdmX. MdmX lacks a nuclear localization signal and nuclear export signal, but 
interaction with Mdm2 and p53 can allow for its translocation into the nucleus (Li et al., 2002; 
Marine and Jochemsen, 2005). The MdmXΔRING mutation, which disrupts Mdm2:MdmX 
heterodimerization, results in increased cytoplasmic MdmX, while the distributions of Mdm2 and 
p53 remain similar to that observed in the wild-type MEFs (Pant et al., 2011). Enrichment of 
cytoplasmic MdmX is also observed in Mdm2C462A MEFs, suggesting that dissociation of Mdm2 
and MdmX may increase the level of cytoplasmic MdmX (Figure 1-4). As MdmX is thought to 
regulate p53 primarily through its ability to directly bind p53 and inhibit its function as a 
transcription factor, changes in the distribution of MdmX may affect its interaction with p53. 
Neither MdmXΔRING nor Mdm2C462Aappear to affect p53 localization in MEF cell culture, 
discouraging the possibility that these changes in MdmX localization result in sequestration of 
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p53 into the cytoplasm. One possible interpretation is that disruption of Mdm2:MdmX interaction 
may enhance cytoplasmic MdmX, potentially decreasing MdmX:p53 interaction in the nucleus. 
Another possibility is that changes in the ratio of cytoplasmic-to-nuclear MdmX affect the 
frequency of Mdm2:MdmX interaction, decreasing the E3 ubiquitin ligase potential of Mdm2. 
Another role of the Mdm2:MdmX heterodimer that has been explored, and is perhaps 
the best supported, is the idea that the dimer of Mdm2 and MdmX, rather than Mdm2 alone, 
functions as the E3 ubiquitin ligase for p53 (Huang et al., 2011). Ubiquitination of Mdm2 is 
reduced in the presence of MdmXC462A compared to wild-type MdmX, which Huang et al. 
extrapolate as indication that disruption of Mdm2:MdmX binding is capable of hindering the E3 
ligase activity of Mdm2 toward p53 as well (Huang et al., 2011). A similar phenomenon has 
been described in vitro; 3 mutations—Mdm2T488D, Mdm2Y489A, and Mdm2Y489D—each disrupt 
Mdm2 E3 ubiquitin ligase activity toward p53, but upon co-expression with MdmX, they regain 
the ability to degrade p53, adding further support to the idea that the importance of 
Mdm2:MdmX interaction lays in the ability of MdmX to influence Mdm2 E3 ubiquitin ligase 
activity (Poyurovsky et al., 2007; Uldrijan et al., 2007). In addition, other RING finger proteins, 
such as the BRCA1-BARD1 heterodimer, demonstrate enhancement of E3 ubiquitin ligase 
activity upon heterodimer formation (Hashizume et al., 2001). On the flip side, the presence of 
the MdmXΔRING mutation, which also disrupts Mdm2:MdmX binding, does not affect the half-lives 
of Mdm2 and p53 or p53 ubiquitination status (Pant et al., 2011). Additionally, while Mdm2 is 
capable of autoubiquitination in vitro, the ability of Mdm2C462A to be degraded normally, despite 
losing the ability to degrade p53, suggests that Mdm2 and p53 are not degraded in the same 
manner and that an outside E3 may be responsible for ubiquitination of Mdm2 in vivo (Fang et 
al., 2000; Honda and Yasuda, 2000; Itahana et al., 2007). In light of this, the fact that 
MdmXC462A disrupts the ubiquitination of Mdm2 is not necessarily a reflection of changes in the 
ability of p53 to be ubiquitinated and subsequently degraded, as ubiquitination of endogenous 
Mdm2 and p53 may not occur through the same mechanism. 
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The interconnected nature of Mdm2, MdmX, and p53 degradation and activation can 
make it difficult to parse out causes and effects. Rather than directly influencing how Mdm2 and 
MdmX interact with p53, heterodimerization may be key due to the effects of interaction on the 
stability of Mdm2 and MdmX, which then ultimately affects p53 stability and activity. The relative 
levels of Mdm2, MdmX, and p53 have been shown to be important in whether interaction 
between these proteins results in degradation, stabilization, or promotion of transcription of one 
another (Linke et al., 2008). Despite its general characterization as an inhibitor of p53 activity, 
upon DNA damage, MdmX is also capable of enhancing p53 stability and activity (Di Conza et 
al., 2012). MdmX interaction with p53 specifically stimulates activity toward the Mdm2 promoter, 
and thus, downregulation of MdmX can result in downregulation of Mdm2 (Biderman et al., 
2012). While MdmX is associated with enhanced Mdm2 transcription, simultaneously, Mdm2 is 
responsible for the degradation of MdmX (de Graaf et al., 2003; Kawai et al., 2003; Pan and 
Chen, 2003). The Mdm2:MdmX interaction plays a central role in MdmX degradation, as MdmX 
rather than Mdm2 is ubiquitinated in the heterodimer, and proper Mdm2:MdmX 
heterodimerization is necessary for degradation of MdmX following DNA damage (Linke et al., 
2008; Wade et al., 2012). In vitro studies also show that MdmX can serve as a competing 
substrate for Mdm2 E3 ligase activity, and thus, when Mdm2:MdmX binding is disrupted and 
MdmX no longer competes with Mdm2 for Mdm2 E3 ligase activity, Mdm2 E3 ligase activity 
toward itself is increased, resulting in overall lower levels of Mdm2 (Linke et al., 2008). This 
competition model directly contradicts evidence based on the MdmXC462A mouse model, in 
which disruption of heterodimerization results in decreased ubiquitination of Mdm2 and 
increased levels of p53 and Mdm2, and further disagrees with data from the Mdm2C462A mouse 
model, in which Mdm2 does not autoubiquitinate, together serving as additional examples of the 
disagreement that exists between in vitro and in vivo modeling of the Mdm2:MdmX:p53 
regulatory pathway (Huang et al., 2011; Itahana et al., 2007). Due to the interconnected and 
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multiple levels of interaction of Mdm2 and MdmX regulation, the relative level of these proteins 
becomes increasingly important, further emphasizing the necessity for in vivo studies. 
 
Conclusions and Dissertation Goals 
Advances and Unknowns in Understanding the Mdm2:MdmX:p53 Complex In Vivo 
Despite the advances that in vivo models have allowed, much remains unknown about 
the specifics of Mdm2:MdmX:p53 interaction and regulation, in part due to incongruences that 
exist among the current models. Additionally, many of the current models offer negative data; 
that is, deletion or mutation results in a nonviable animal. While this information is very useful in 
broadening our knowledge, embryonic lethality limits the scope of studies that can be performed 
and, with that, what can be further extrapolated. To address the issue of embryonic lethality, 
many of the Mdm2 and MdmX models are placed into an inducible, transcriptionally dead, or 
hypomorphic p53 background (i.e., p53ER/–, p53515A, p53Neo), and while this does allow for further 
investigation, it also introduces potentially confounding variability into an already intricate 
regulatory network. For example, while p53 is generally characterized to be primarily nuclear, 
p53515A is equally represented in the cytoplasmic and nuclear fractions (O'Brate and 
Giannakakou, 2003; Pant et al., 2011). The level of cytoplasmic p53 appears to be increased in 
the presence of the MdmXΔRING mutant, but because the subcellular distribution of p53 is already 
distorted, it is difficult to conclude whether the changes in localization are due to the 
MdmXΔRING mutant increasing cytoplasmic retention or nuclear export of p53, or if it is an effect 
of the p53515A mutation itself, independent of MdmX mutation status. 
Even with disagreements among the various models, as well as contradictions 
between in vivo and in vitro studies, the combined analyses of the models at hand have further 
clarified the p53 regulatory network. One concept that is supported consistently by each of 
these models is that Mdm2:MdmX heterodimerization is a critical component of proper p53 
regulation in vivo. A few key questions remain: 1) What is the functional importance of 
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Mdm2:MdmX heterodimerization in p53 regulation, and why are Mdm2:Mdm2 or MdmX:MdmX 
homodimers unable to function in this same manner? 2) How is Mdm2 degraded in vivo? 3) 
What is the relationship between p53 stabilization and p53 activity? In vitro studies suggest that 
loss of Mdm2 E3 ligase activity may stabilize p53, however, loss of Mdm2:p53 binding is 
necessary to activate p53, returning us to the idea that Mdm2 functions via a dual mechanism to 
regulate p53 (Wade et al., 2012). In contrast, the Mdm2C462A mouse model suggests that p53 
binding alone is not sufficient for inhibiting p53 activity in vivo, but as noted earlier, the 
Mdm2C462A mutation disrupts Mdm2:MdmX binding in addition to Mdm2 E3 ligase activity, and 
the significance of this loss of heterodimerization on p53 regulation may be greater than initially 
believed (Itahana et al., 2007). The idea of a dual mechanism for Mdm2 regulation of p53 may 
feel full circle, but rather than Mdm2:p53 binding alone or the E3 ligase function of Mdm2 
playing the critical role in this dual mechanism, it now appears as if Mdm2 interaction via its 
RING finger domain with MdmX may be at the heart of its ability to properly and efficiently 
regulate p53 stability and activity. Through further experimentation with the models previously 
developed, as well as the development of additional mouse models, specifically, a model 
evaluating the effect of disrupting Mdm2 E3 ligase activity alone without affecting Mdm2:MdmX 
binding, these questions can be addressed, bringing us one step closer to understanding how 
p53, a protein critical in tumor suppression, metabolism, and reproduction, is regulated at 
physiological levels. The use of mouse models allows for a closer look at how the p53 
regulatory network is functioning at the level of the organism and under conditions of 
endogenous protein expression, allowing for a greater understanding of the misregulation of this 
pathway in cancer and other diseases, thereby opening the door for better potential therapeutic 
targets.  
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p53 Pathway in Disease and Cancer Therapy 
Mutation of p53, as observed in Li-Fraumeni syndrome, has serious clinical 
consequences for affected individuals. While the number of individuals affected by Li-Fraumeni 
syndrome is relatively low, more than 50% of all tumors harbor mutations or deletions in p53 
(Hainaut et al., 1997; Levine, 1997). Further, in tumors with intact p53, gene amplification or 
otherwise aberrant expression of Mdm2 and MdmX is frequently observed, implicating 
misregulation of the p53 pathway in these malignancies as well (Danovi et al., 2004; Momand et 
al., 1998; Ramos et al., 2001). In a panel of human breast cancers with wild type p53, extensive 
phosphorylation of Thr18 and Ser20 was observed, providing a clinical example of the 
correlation between disruption of Mdm2:p53 interaction, aberrant regulation of p53, and cancer 
(Craig et al., 1999). 
In light of the tumor suppressive functions of p53 and the high frequency of p53 
misregulation in a broad range of cancer types, the possible implications of an anti-cancer 
therapeutic targeting the p53 pathway are far reaching. A number of potential therapeutic 
compounds have been developed to correct dysfunction in the p53 pathway; the mechanism for 
reactivation of p53 in the vast majority of these compounds is through disruption of Mdm2:p53 
interaction (Hoe et al., 2014). Identification and development of 4,5-dihydroimidazoline, now 
better known as nutlin, as a small molecule inhibitor capable of binding to Mdm2 to inhibit 
Mdm2:p53 interaction was a critical first step in the field of p53 therapeutics; characterization of 
the interaction between the nutlin 3a isomer and Mdm2 served as the basis for the development 
of a number of inhibitors aiming to improve Mdm2:p53 disruption. (Hoe et al., 2014; Vassilev et 
al., 2004). Phase I clinical trials of RG7112, a nutlin family Mdm2 antagonist, suggest it to be a 
promising new compound in the treatment of solid tumors with wild type p53 (Tovar et al., 2013).  
In addition to demonstrating potent efficacy in reactivation of p53 signaling, RG7112 is resistant 
to oxidation, an improvement upon previous compounds (Tovar et al., 2013). 
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Another promising class of compounds with strong affinity for Mdm2, spirooxindole-
based molecules, similarly function to activate p53 via disruption of Mdm2:p53 interaction. 
Treatment with the compound MI-219, currently in phase I clinical trials, led to increased p53 
levels and activity, however, the development of diasteromeric spirooxindoles such as MI-888 
has allowed for complete tumor regression of osteosarcoma tumor xenografts in SCID mice, 
providing further encouragement for the possible success of this class of compounds (Shangary 
et al., 2008; Zhao et al., 2013).   
In contrast with the majority of Mdm2 antagonists, which target the N-terminal p53-
binding domain of Mdm2, a group of synthetic analogues of 5-deazaflavin compounds bind to 
the RING finger domain of Mdm2 (Roxburgh et al., 2012). Treatment with 5-deazaflavins inhibits 
ubiquitination of p53, increasing p53 stability and activity, and suggesting that targeted inhibition 
of the Mdm2 RING finger domain may be a valuable avenue for pharmacological reactivation of 
p53.  
Following a number of Phase I and Phase II clinical trials, HDAC inhibitors are gaining 
traction as an option for anti-cancer therapeutics due to their ability to alter gene expression to 
promote apoptosis, cell cycle arrest, and differentiation in tumor cells (Johnstone, 2002; Minucci 
and Pelicci, 2006; Prince et al., 2009). While HDAC inhibitors affect gene expression through 
increased histone acetylation, they also function to activate the p53 pathway by increasing p53 
acetylation, which in turn can increase apoptosis and cellular senescence (Harms and Chen, 
2007).  
A second area of focus in the field of p53-targeted therapeutics is the reactivation of 
mutant p53. Phase I clinical studies from a number of groups, including Amgen, Novartis and 
Aprea, demonstrate small molecules such as PRIMA-1MET to bind to mutant p53 and induce 
apoptosis in cancer cells with mutant p53 (Hoe et al., 2014; Lehmann et al., 2012; Zache et al., 
2008; Zandi et al., 2011). While an exact mechanism of action is yet to be determined, it is 
proposed that PRIMA-1MET and its structural analogues induce apoptosis through promoting 
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covalent reactions with thiol groups in mutant p53 to restore native protein structure 
confirmation (Lambert et al., 2009).   
Considering the mechanism of action for the majority of existing p53-targeted anti-
cancer therapeutics, including nutlins, 5-deazaflavins, and spirooxindole-based molecules, is 
based on disruption of Mdm2-mediated regulation of p53, establishing an accurate and robust 
understanding of this regulatory pathway in vivo is essential for the implementation of these 
therapeutics in the clinic. Here, in the proceeding work we have generated and characterized a 
novel Mdm2 knock-in mouse model harboring a tyrosine-to-alanine substitution at the 487 
residue of Mdm2, Mdm2Y487A. The single point mutation in Mdm2Y487A mice results in disruption 
of Mdm2 E3 ligase activity, but maintained interaction of Mdm2 with both p53 and MdmX. In 
conjunction with the existing mouse models, the generation and characterization of the 
Mdm2Y487A mouse has provided valuable insight into p53 regulation in vivo, and will be a useful 
tool in the continued investigation of the p53 pathway.   
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Figure 1-1. Structure Domain Model for p53, Mdm2, and MdmX. 
Model depicting important protein domains for activity and interaction of p53, Mdm2, and 
MdmX including: p53 transactivation domain (TAD), DNA binding domain, tetramerization 
domain (TD), C-terminal domain (C-term), nuclear localization signal (NLS), nuclear export 
signal (NES), nucleolar localization signal (NoLS), acidic domain (ACIDIC), and zinc finger 
domain (ZF). Bars above the protein represent approximate locations for binding with the 
indicated proteins. 
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Figure 1-2. Model of Mdm2, MdmX Mediated Regulation of p53. 
 Model depicting key interactions in Mdm2:MdmX mediated regulation of p53 activity and 
stability.  Mdm2 and MdmX interact with one another via their respective C-terminal RING 
finger (RF, yellow) domains to form a heterodimer.  The N-terminal p53 binding domain (light 
blue) of both Mdm2 and MdmX allows for direct binding to the p53 transactivation domain, 
inhibiting p53 activity as a transcription factor for its target genes. The RF domain of Mdm2 
confers its E3 ubiquitin ligase function. Mdm2-mediated ubiquitination (Ub, green) of p53 
(pink) promotes the export of p53 from the nucleus to the cytoplasm, and subsequent 
degradation by the 26 S proteasome.  
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Genotype  Model 
WT 
background 
p53
-/- 
background 
p53
-/-
 
Mdm2
-/-
 
MdmX
-/-
 
Developmentally 
normal; early 
susceptibility to tumor 
formation 
Lethal between E4.5 
and E7.5 
Increased apoptosis 
Lethal between E7.5 
and E8.5 
Decreased cellular 
proliferation  
Lethal prior to E7.5 
Decreased cellular 
proliferation 
N/A 
Viable 
Viable 
Viable 
MdmX
C462A
 
Mdm2
C462A
 
Viable 
Lethal at ~E9.5 
Decreased cellular 
proliferation; increased 
apoptosis 
MdmX
ΔRING
 Viable 
Lethal at ~E9.5 
Figure 1-3. Phenotypes of p53, Mdm2, and MdmX Mutant Mice. 
Effects of p53, Mdm2, and MdmX deletion and mutation on mouse development in a wild-
type (WT) and p53-Null (p53
-/-
) background. 
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A 
B 
Figure 1-4. Mdm2:MdmX Heterodimerization Affects MdmX Localization. 
A) Subcellular localization of Mdm2+/+;p53ER/– and Mdm2C462A/C46A;p53ER/– MEFs. All cells 
were treated with 4-OHT for 24 hours. PARP and β-tubulin were used as nuclear and 
cytoplasmic markers, respectively.  
 
B) Quantitation of MdmX as measured by ImageJ. Total and cytoplasmic values were 
normalized to β-tubulin, and nuclear signal was normalized to PARP. All values are 
expressed as relative to the wild-type value for the respective subcellular fraction. 
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2. CHAPTER 2: REGULATION OF P53 BY MDM2 E3 LIGASE FUNCTION IS DISPENSABLE 
IN EMBRYOGENESIS AND DEVELOPMENT BUT ESSENTAIL IN RESPONSE TO DNA 
DAMAGE2 
 
INTRODUCTION 
Classically, TP53 has been characterized as a tumor suppressor gene, functioning as a 
transcription factor for a number of genes important in cell cycle arrest, apoptosis, and 
senescence (Levine, 1997).  In more recent years, a multitude of research has emerged 
broadening the role of p53 from an overarching tumor suppressor to a gene and protein product 
with critical roles in meiosis, reproduction, and metabolism (Deisenroth and Zhang, 2011; 
Levine et al., 2011; Lu et al., 2010; Vousden and Ryan, 2009).   
The oncoprotein Mdm2 is generally accepted to function as the primary negative 
regulator of p53 (Kruse and Gu, 2009; Wade et al., 2010).  The RING finger domain of Mdm2 
confers its E3 ubiquitin ligase activity, and through this function Mdm2 controls p53 stability, 
targeting it for export from the nucleus and subsequent degradation by the proteasome (Haupt 
et al., 1997; Honda et al., 1997; Kubbutat et al., 1997).  In addition to regulating p53 protein 
levels, Mdm2 also regulates p53 activity by binding via its N-terminus directly to the p53 
transactivation domain (Momand et al., 1992; Oliner et al., 1993).  In vivo, deletion of Mdm2 
results in high levels of p53 protein accumulation and transcriptional activity, and early 
                                               
2 This chapter is adapted from a research article accepted for publication in Cancer Cell. The 
concept of the project was developed by myself and Yanping Zhang. Jikyoung Park performed 
the gene targeting for the development of the Mdm2Y487A/Y487A knock-in mouse. Aiwen Jin 
performed the p53:p300 immunoprecipitation, and acetyl-53 and phospho-p53 analysis. I 
performed all other experiments and wrote the manuscript; the manuscript was finalized by 
Yanping Zhang. The original citation is as follows: Laura Tollini, Aiwen Jin, Jikyoung Park, and 
Yanping Zhang. (2014) Regulation of p53 by Mdm2 E3 Ligase Function is Dispensable in 
Embryogenesis and Development but Essential in Response to DNA Damage. Cancer Cell [in 
press]. 
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embryonic lethality in Mdm2-/- mice; this phenotype is rescued by concomitant deletion of p53, 
further demonstrating the essential role of Mdm2 in p53 regulation (Jones et al., 1995; Montes 
de Oca Luna et al., 1995).  
MdmX, an Mdm2 homologue, is similarly capable of binding at its N-terminus to the p53 
transactivation domain to control p53 activity, however, MdmX does not harbor intrinsic E3 
ubiquitin ligase activity (Jackson and Berberich, 2000; Poyurovsky et al., 2007; Shvarts et al., 
1996).  Similar to Mdm2 null mice, p53-dependent early embryonic lethality is also observed in 
MdmX null mice (Parant et al., 2001).  While the early embryonic lethality observed in both 
Mdm2 and MdmX knockout mouse models suggests that individually Mdm2 and MdmX play 
unique and critical roles in the regulation of p53 stability and activity, the embryonic lethality 
observed in two recently developed MdmX knock-in mouse models that disrupt Mdm2:MdmX 
heterodimerization suggests that the ability of these two proteins to interact at their respective 
C-terminal RING finger domains and function collaboratively is essential for p53 regulation 
(Huang et al., 2011; Pant et al., 2011).  
Mdm2:MdmX heterodimerization can also be disrupted by mutation of the Mdm2 RING 
finger domain, as is observed in the Mdm2C462A knock-in mouse model (Clegg et al., 2012; 
Itahana et al., 2007).  The single amino acid substitution of cysteine to alanine at the 462 amino 
acid residue of murine Mdm2 disrupts Mdm2:MdmX interaction and ablates Mdm2 E3 ligase 
activity, but maintains Mdm2:p53 interaction. Homozygosity of the Mdm2C462A mutation results in 
early embryonic lethality due to excessive p53 activation, suggesting that Mdm2:p53 binding 
alone is not a sufficient mechanism for controlling p53 activity, and calling into question the 
extent to which Mdm2:p53 interaction can regulate p53 activity in vivo (Itahana et al., 2007).  
Because both Mdm2 E3 ligase activity and Mdm2:MdmX heterodimerization are disrupted by 
the Mdm2C462A mutation, the independent effect of loss of each of these RING finger domain 
functions cannot be deduced from this model. Therefore, the in vivo role of Mdm2 E3 ubiquitin 
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ligase activity, believed to be the most critical function of Mdm2 in p53 regulation, is yet to be 
unequivocally addressed.  
To investigate the in vivo significance of Mdm2 E3 ubiquitin ligase function without the 
confounding complications that accompany disruption of Mdm2:MdmX interaction, we have 
developed an Mdm2 knock-in mouse harboring a single amino acid substitution of tyrosine to 
alanine at the 487 residue, C-terminal of the RING finger domain. The corresponding mutation 
in human Mdm2, Mdm2Y489A, has been shown in in vitro studies to disrupt Mdm2 E3 ligase 
activity, while maintaining Mdm2:MdmX heterodimerization (Poyurovsky et al., 2007; Uldrijan et 
al., 2007), effectively allowing for separation of these two Mdm2 RING finger domain functions.  
Quite surprisingly, the Mdm2Y487A mouse model indicates that robust Mdm2 E3 ubiquitin ligase 
function is not required for proper embryogenesis, normal development, or survival under 
unstressed conditions, but rather is a function critical in the recovery process following p53 
activation during the cellular stress response.  
 
RESULTS 
Mdm2Y487A/Y487A Mice are Viable and Phenotypically Normal 
In vitro, the extreme C-terminal 5 amino acids of Mdm2 are necessary for E3 ubiquitin 
ligase activity; point mutations within this region disrupt Mdm2 E3 ubiquitin ligase activity, 
without affecting its ability to homo-oligomerize with Mdm2 or hetero-oligomerize with MdmX 
(Poyurovsky et al., 2007; Uldrijan et al., 2007).  Specifically, retention of an aromatic amino acid 
at the 489 residue of human Mdm2 is essential for Mdm2 E3 ligase activity, and mutation of 
tyrosine 489 to alanine ablates Mdm2 E3 ligase activity without affecting its interaction with 
MdmX (Uldrijan et al., 2007).  To assess if the Mdm2Y489A mutant maintains this phenotype in 
vivo, site directed mutagenesis was used to introduce a Tyr-to-Ala substitution at the 
corresponding amino acid residue in mouse Mdm2, Y487, to a PGK neo targeting vector, 
described previously in the development of Mdm2C462A knock-in mice (Itahana et al., 2007) 
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(Figure 2-1). Correct substitution of TAC to GCA in exon 12 of Mdm2 was confirmed via DNA 
sequencing.  The targeting vector containing the Mdm2 (Y487A) substitution was injected into 
129/Sv embryonic stem (ES) cells, and the ES cells were then microinjected into C57BL/6 
blastocysts to produce chimeras.  Following mating of chimeric male mice with C57BL/6 
females, PCR (Figure 2-2A) and sequencing (Figure 2-2B) of mouse genomic DNA from toe 
biopsies was used to confirm germline transmission of the Mdm2Y487A mutation.  The neomycin 
cassette was removed from the neo-Mdm2Y487A/+ mice by mating against an EIIa-Cre transgenic 
mouse, which targets expression of Cre recombinase early in mouse embryogenesis, providing 
fairly ubiquitous excision of the marker from the targeted allele in the mouse.  Further 
intercrossing of Cre-treated mice was performed to outbreed the Cre-transgene, followed by five 
generations of backcrossing to C57BL/6 to generate Mdm2Y487A/Y487A mice with a 97% pure 
C57BL/6 genetic background. 
Mice heterozygous for the Mdm2Y487A mutation were viable, and appeared phenotypically 
normal and fertile.  Surprisingly, upon intercrossing Mdm2Y487A/+ mice, mice homozygous for the 
mutation were observed at normal Mendelian ratios at birth, indicating that no embryonic 
lethality is associated with homozygosity of this mutation (Figure 2-3A).  To determine if the 
mutation had effects later in development, a cohort of male and female mice was assembled 
and monitored weekly for weight, activity, and overt signs of disease.  Both male and female 
homozygous mutant mice appeared to be somewhat smaller than their heterozygous and wild 
type (WT) counterparts (Figure 2-4).   Mdm2Y487A/Y487A mice did not demonstrate any notable 
differences in disease occurrence, spontaneous tumor formation, or mortality compared to WT 
mice (Figure 2-3B). 
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Endogenous Mdm2Y487A Does Not Degrade p53 and Maintains the Ability to Bind MdmX and 
p53 
 
The viability and apparent normality of Mdm2Y487A/Y487A mice was surprising; and thus we 
examined endogenous Mdm2Y487A to determine both its E3 ubiquitin ligase function for p53 
degradation, and its ability to interact with MdmX.  In mouse embryonic fibroblasts (MEFs), as 
well as some tissue types, such as the spleen and testes, increased levels of p53 protein were 
observed in the Mdm2Y487A/Y487A mutant compared to the WT, suggestive of disrupted Mdm2 E3 
ligase activity for p53 degradation (Figure 2-5).  The effect of Mdm2Y487A on p53 stability in 
tissue was generally less dramatic compared to that observed in MEFs.  We observed 
somewhat higher p21 levels in some Mdm2Y487A/Y487A tissues potentially indicative of higher p53 
activity.   
To more directly analyze the E3 ligase activity of Mdm2Y487A for p53, a half-life assay 
using the protein synthesis inhibitor cycloheximide was performed on Mdm2+/+ and 
Mdm2Y487A/Y487A MEFs.  In the presence of WT Mdm2, p53 has a half-life of approximately 30 
minutes, however, in the presence of Mdm2Y487A, no degradation of p53 was observed as late 
as 3 hours after cycoheximide treatment (Figure 2-6A).  Further, following treatment with the 
proteasome inhibitor MG-132, p53 was significantly accumulated in WT MEFs, whereas in 
Mdm2Y487A/Y487A MEFs no further accumulation of p53 was observed (Figure 2-7).  The increased 
levels of p53 under untreated conditions and the lack of p53 accumulation by MG-132 treatment 
in Mdm2Y487A/Y487A MEFs suggest that the loss of Mdm2 E3 ligase activity significantly disrupts 
proteasome-mediated degradation of p53, and supports the role of Mdm2 as the primary E3 
ubiquitin ligase for p53 degradation in vivo.  Taken together, this data is consistent with previous 
in vitro studies showing that Mdm2Y489A does not degrade p53 (Poyurovsky et al., 2007; Uldrijan 
et al., 2007), demonstrating that endogenous Mdm2Y487A has similarly lost the ability to degrade 
p53.   
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While Mdm2Y487A/Y487A homozygous mice are viable in the presence of p53, in order to 
directly compare this mutant to the embryonic lethal Mdm2C462A/C462A mutant (Itahana et al., 
2007), both mutants were placed in an inducible p53 background, p53ERTAM (p53ER hereafter) 
(Christophorou et al., 2005).  In the p53ER background, endogenous p53 is substituted with a 
p53 fusion protein, consisting of a full length p53 fused at its C-terminus to the hormone binding 
domain of a modified estrogen receptor, providing the ability for p53 to be turned “on” and “off” 
in the presence and absence of 4-hydroxytamoxifen (4-OHT), respectively (Christophorou et al., 
2005).  Similar to MEFs harboring the Mdm2C462A RING domain mutant, half-life assay of 
Mdm2Y487A/Y487A;p53ER/- MEFs demonstrated no degradation of p53ER (Figure 2-6B). Furthermore, 
as demonstrated by immunoprecipitation of Mdm2 in MEFs, Mdm2Y487A mutant protein maintains 
the ability to bind to MdmX, p53, and p53ER (Figure 2-8).  
Mdm2 has previously been identified as the E3 ligase responsible for MdmX degradation 
(Kawai et al., 2003; Linke et al., 2008; Pan and Chen, 2003), and unsurprisingly, in the 
presence of Mdm2Y487A, stabilization of MdmX is observed (Figure 2-8). A cycloheximide 
mediated half-life assay was performed to further explore the effect of Mdm2Y487A on MdmX 
degradation, and the results indicated that the degradation of MdmX is partially attenuated in 
the presence of Mdm2Y487A (Figure 2-9).  Moreover, the Mdm2Y487A mutation did not appear to 
affect the subcellular localization of p53, MdmX, or Mdm2 itself; while total protein levels of p53, 
Mdm2, and MdmX are increased in Mdm2Y487A/Y487A MEFs, the subcellular distribution of each of 
these proteins remained similar to that observed in WT MEFs (Figure 2-10).  
 
Disruption of Mdm2 E3 Ligase Activity Does Not Affect Mdm2 Stability 
Regulation of Mdm2 stability is believed to be mediated primarily through 
autoubiquitination (Fang et al., 2000; Honda and Yasuda, 2000; Stommel and Wahl, 2004); 
however, the advent of the Mdm2C462A knock-in mouse provided strong evidence suggesting 
that Mdm2 does not in fact autoubiquitinate in vivo, but that instead an unknown E3 ubiquitin 
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ligase(s) is responsible for Mdm2 degradation (Itahana et al., 2007).  Nonetheless, the 
Mdm2C462A model has a caveat: the Mdm2C462A mutation disrupts Mdm2 RING structure, along 
with Mdm2 E3 ligase function and Mdm2:MdmX binding, and the possibility of this structural 
change adversely affecting Mdm2 stability cannot be ruled out.  With the Mdm2Y487A model we 
wanted to further explore the mechanism of Mdm2 degradation in vivo.  To this end, a 
cycloheximide mediated half-life assay was used to examine the degradation of Mdm2 in WT 
and Mdm2Y487A/Y487A MEFs.  Despite disrupting Mdm2-mediated degradation of p53 and MdmX 
(Figure 2-6, 2-7, and 2-9), and although Mdm2 is present at higher levels in Mdm2Y487A/Y487A 
MEFs compared to WT MEFs (Figure 2-8), Mdm2 was degraded at a similar rate in 
Mdm2Y487A/Y487A MEFs as in WT MEFs (Figure 2-11A).  Additionally, a normal rate of Mdm2 
degradation was observed in Mdm2Y487A/Y487A;p53ER/- MEFs (Figure 2-11B), similar to the 
previous observations made in Mdm2C462A/C462A;p53ER/- MEFs (Itahana et al., 2007).  To further 
investigate the mechanism of Mdm2 degradation, a p53-null genetic background was utilized in 
order to study the effect of disrupted Mdm2 E3 ligase activity on Mdm2 stability, while avoiding 
the confounding effects of p53 transcriptional activation of Mdm2.  MG-132 treatment resulted in 
similar stabilization of Mdm2 in Mdm2+/+;p53-/-, Mdm2Y487A/Y487A;p53-/-, and Mdm2C462A/C462A;p53-/- 
MEFs, indicating that the degradation observed is mediated by proteasomal proteolysis, and 
further suggesting the role of outside E3 ligases in Mdm2 ubiquitination and degradation (Figure 
2-12).   
While both Mdm2Y487A and Mdm2C462A disrupt p53 degradation and maintain Mdm2 
degradation, the unique location of each of these residues in different regions of the C-terminus 
previously demonstrated to be important for Mdm2 E3 ubiquitin ligase function suggests that the 
specific mechanism of disruption of Mdm2 E3 ligase activity is likely different between these two 
Mdm2 mutants (Figure 2-13) (Poyurovsky et al., 2007; Uldrijan et al., 2007). The observation of 
a second, mechanistically unique, E3 inactive Mdm2 mutant capable of maintaining normal 
35 
 
Mdm2 degradation provides additional evidence against the necessity of autoubiquitination for 
in vivo degradation of Mdm2.  
 
Loss of Mdm2:MdmX Heterodimerization Correlates with Increased p53 Activity  
In light of the embryonic lethality observed in MdmXΔRING (Pant et al., 2011), MdmXC462A 
(Huang et al., 2011), and Mdm2C462A (Itahana et al., 2007) homozygous mutants, all of which 
disrupt Mdm2:MdmX heterodimerization, we sought to use the Mdm2Y487A model, which 
maintains heterodimerization, in conjunction with the Mdm2C462A model for a comparative study 
of the effect of Mdm2:MdmX heterodimerization on p53 activity independent of Mdm2 E3 ligase 
activity. Due to the embryonic lethality of Mdm2C462A/C462A homozygotes in the presence of WT 
p53, the p53ER/- background was utilized to allow for a side-by-side comparison of MEFs with 
and without Mdm2:MdmX heterodimerization. To this end, qRT-PCR was performed to compare 
the relative mRNA levels of p53 target genes in MEFs. Upon activation of p53 with 4-OHT, 
Mdm2Y487A/Y487A;MdmX+/+;p53ER/- (487/487) MEFs maintained similarly low levels of mRNA in a 
number of p53 target genes, including Mdm2, p21, APAF1, and Bax, as compared to 
Mdm2+/+;MdmX+/+;p53ER/- (WT) MEFs (Figure 2-14A-D). Disruption of Mdm2:MdmX 
heterodimerization via concomitant deletion of MdmX, as in Mdm2Y487A/Y487A;MdmX-/-;p53ER/- 
(487/487;MdmX-/-) MEFs, or via Mdm2 RING finger mutation, as in 
Mdm2C462A/C462A;MdmX+/+;p53ER/- (462/462) MEFs, was correlated with higher mRNA levels of 
the p53 target genes assessed, indicative of higher p53 activity in the absence of Mdm2:MdmX 
interaction (Figure 2-14A-D). This suggests that the ability of Mdm2 to heterodimerize with 
MdmX, but not its E3 ligase activity, is essential for suppression of p53 activity.  
To elucidate the mechanism by which the Mdm2:MdmX heterodimer suppresses p53 
activity we assessed p53 acetylation, an important post-translational modification for the 
enhancement of p53 activity (Gu and Roeder, 1997). In Mdm2C462A/C462A;p53ER/- MEFs lacking 
Mdm2:MdmX heterodimerization, a higher level of acetylated p53 was observed compared to 
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either Mdm2Y487A/Y487A;p53ER/- MEFs, or Mdm2+/+;p53ER/- MEFs, both of which retain intact 
Mdm2:MdmX heterodimer formation and demonstrated similar low levels of p53 acetylation 
(Figure 2-15A). Additionally, loss of heterodimerization correlated with increased binding 
between p53 and the histone acetyltransferase, p300 (Figure 2-15B). This data suggests that 
Mdm2:MdmX heterodimerization functions to control p53 activity, at least in part, through 
inhibiting p53:p300 interaction and p53 acetylation.  
At the protein level, it is apparent that the loss of Mdm2:MdmX heterodimerization, as 
occurs in the Mdm2C462A mutant (Mdm2C462A/C462A;MdmX+/+;p53ER/-), is associated with higher 
levels of p53, as well as the p53 downstream targets Mdm2 and p21 (Figure 2-16, Lanes 10-12), 
compared to the levels observed in either Mdm2+/+;MdmX+/+;p53ER/- (Figure 2-16, Lanes 1-3) or 
Mdm2Y487A/Y487A;MdmX+/+;p53ER/- MEFs (Figure 2-16, Lanes 4-6), which both retain Mdm2:MdmX 
interaction. Furthermore, concomitant deletion of MdmX, effectively functioning to disrupt 
Mdm2:MdmX heterodimerization in the Mdm2Y487A mutant (Mdm2Y487A/Y487A;MdmX-/-;p53ER/-), 
resulted in Mdm2, p21, and p53 levels much higher than in the presence of the Mdm2Y487A 
mutation alone (Mdm2Y487A/Y487A;MdmX+/+;p53ER/-) (Figure 2-16, compare Lanes 7-9 with Lanes 
4-6), and similar to those observed in Mdm2C462A/C462A;MdmX+/+;p53ER/- MEFs (Figure 2-16, 
Lanes 10-12). While higher levels of p53 are observed in Mdm2Y487A/Y487A;MdmX+/+;p53ER/- MEFs 
(Figure 2-16, Lanes 4-6) compared to Mdm2+/+;MdmX+/+;p53ER/- MEFs (Figure 2-16, Lanes 1-3), 
as would be expected in the absence of Mdm2 E3 ligase activity, the additional disruption of the 
Mdm2:MdmX interaction resulted in further stabilization of p53 and its downstream targets, as 
observed in Mdm2Y487A/Y487A;MdmX-/-;p53ER/- (Figure 2-16, Lanes 7-9) and 
Mdm2C462A/C462A;MdmX+/+;p53ER/- (Figure 2-16, Lanes 10-12) MEFs. As some prior studies, as 
well as our own in vitro study of human Mdm2Y489A and mouse Mdm2Y487A (Figure 2-17), have 
suggested that MdmX enables and/or enhances Mdm2 E3 ligase function (Okamoto et al., 2009; 
Poyurovsky et al., 2007; Uldrijan et al., 2007), we compared p53 stabilization in the presence or 
absence of MdmX. In both the presence (Figure 2-18A) and the absence (Figure 2-18B) of 
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MdmX, p53ER was reduced to equal levels following activation by 4-OHT, indicating that at least 
under unstressed conditions the degradation of p53 by Mdm2 does not require MdmX binding. 
We noticed that genetic disruption of Mdm2:MdmX interaction, either from the absence 
of MdmX (Mdm2Y487A/Y487A;MdmX-/-;p53ER/-) or mutation of Mdm2 
(Mdm2C462A/C462A;MdmX+/+;p53ER/-), correlated with increased p53 protein levels upon 4-OHT-
mediated induction of p53 activity; mRNA analysis suggests that in the absence of Mdm2:MdmX 
heterodimerization, transcription of p53 itself is increased (Figure 2-14E). Collectively, these 
data implicate the Mdm2:MdmX heterodimer not only in playing a critical role in suppressing p53 
transcriptional activity, but also in regulating p53 protein levels independent of Mdm2 E3 ligase 
function.  
 
Mdm2 E3 Ligase Function is Necessary for Recovery from DNA Damage 
Taking into account the outward normalcy of Mdm2Y487A/Y487A mice under basal conditions, 
despite disruption of Mdm2 E3 ligase activity, we wanted to explore if and when the E3 ubiquitin 
ligase function of the Mdm2 RING domain is necessary. As a transcriptional target of p53, 
Mdm2 transcription is stimulated by p53 following activation by a number of stimuli, presumably 
to degrade p53 and return it to pre-stress levels, and effectively forming a feedback loop 
between Mdm2 and p53 (Barak et al., 1993; Juven et al., 1993). With this in mind, we sought to 
test whether the absence of Mdm2 E3 ligase activity, an essential component of the Mdm2-p53 
negative feedback loop, affects the p53-mediated stress response. To this end, qRT-PCR was 
utilized to analyze the mRNA levels of p53 target genes in WT and Mdm2Y487A/Y487A MEFs. Prior 
to stress, WT and Mdm2Y487A/Y487A MEFs exhibited relatively low levels of mRNA in a number of 
well-characterized p53 target genes, including Mdm2, the cell cycle regulator p21, and the pro-
apoptotic genes Bax, APAF1, and TIGAR (Figure 2-19). However, following UV irradiation (IR), 
Mdm2Y487A/Y487A MEFs demonstrated significantly higher mRNA levels of the p53 target genes 
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assessed compared to WT MEFs, indicative of higher levels of p53 activity in the absence of 
Mdm2 E3 ligase function (Figure 2-19).   
To determine if the increased p53 activity observed was unique to UV activation of the 
p53 pathway, or if it was a more universal response, qRT-PCR was utilized to analyze the 
mRNA levels of the above-mentioned p53 target genes in WT and Mdm2Y487A/Y487A MEFs 
following additional forms of DNA damage, including 5 Gy  IR, and 1 µM doxorubicin, as well 
as ribosomal stress, as induced by a low dose (5 nM) of actinomycin D (Iapalucci-Espinoza and 
Franze-Fernandez, 1979; Perry and Kelley, 1970). Regardless of stimuli, Mdm2Y487A/Y487A MEFs 
were observed to have increased mRNA levels compared to WT MEFs in all of the p53 target 
genes analyzed, although the magnitude of activation of the target genes varied between 
treatments (Figure 2-20). These data suggest that disruption of Mdm2 E3 ligase function 
correlates with hyper-p53 activity following stimulation of the p53 stress response pathway. 
To further investigate the effect of loss of Mdm2 E3 ligase activity in the p53 stress 
response pathway, we assessed p53 phosphorylation as an additional indicator of p53, as well 
as p53 stability. Under unstressed conditions (0 h), despite significant differences in total p53 
levels, Mdm2Y487A/Y487A MEFs demonstrated low p53 activity as indicated by levels of p53 
phosphorylation (Figure 2-21), p21 protein expression (Figure 2-5 and Figure 2-21A-B), and 
mRNA expression of number of p53 target genes (Figure 2-19 and Figure 2-20). DNA damage 
resulted in the rapid increase of phosphorylated p53 in both WT and Mdm2Y487A/Y487A MEFs; the 
dynamics of this initial increase were similar between genotypes and suggested that p53 must 
be appropriately modified postranslationally for activity. While the levels of phosphorylated p53 
in WT MEFs decreased towards basal levels by 24 hours after each treatment, in contrast, in 
Mdm2Y487A/Y487A MEFs DNA damage resulted in sustained high levels of phosphorylated p53 
(Figure 2-21). Similar to the trend observed in phosphorylated p53, following  IR, UV IR, or 
doxorubicin induced DNA damage, WT MEFs demonstrated initial stabilization of total p53, 
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followed by a return towards basal levels by 24 hours; in the mutant MEFs, however, total p53 
levels continued to increase at 24 hours post-treatment (Figure 2-21A-B and Figure 2-22A-B). 
The continued increase of total p53 protein in the mutant MEFs after DNA damage is likely due 
to the combined effect of increased p53 transcription (Raman et al., 2000; Webster and Perkins, 
1999) (Figure 2-23), increased p53 translation (Candeias et al., 2008; Gajjar et al., 2012; Takagi 
et al., 2005), and the inability of the Mdm2Y487A mutant to degrade p53. The effect of increased 
levels of total p53, as well as phosphorylated p53, and the corresponding increase in p53 
activity in Mdm2Y487A/Y487A MEFs compared to WT MEFs following exposure to DNA damaging 
reagents is further reflected in increased G2 arrest (Figure 2-24) and decreased cell survival 
(Figure 2-25). Additionally, we observed that the oxidative stress of standard cell culture 
conditions compared to 3% O2, which better emulates physiological levels of oxygen, was 
sufficient to increase p53 levels and reduce cell growth in otherwise untreated, unstressed 
MEFs (Figure 2-26). 
In addition to DNA damage, in response to non-DNA damaging reagents, such as low 
levels of actinomycin D, a similar pattern of p53 stabilization was observed (Figure 2-22C). 
Together, these data indicate that the Mdm2 E3 ligase function is critical for controlling the 
magnitude of p53 activity in response to stress, and restoring p53 to basal levels after stress.   
 
Mdm2Y487A/Y487A Mice Demonstrate Increased Radiosensitivity 
The enhanced p53 stabilization and activity observed in Mdm2Y487A/Y487A MEFs following 
stress, and the apparent inability of the cells to recover following activation of the p53-mediated 
stress response, pointed to the importance of Mdm2 E3 ligase function in regulating p53 
following exposure to stressors. To test if the aberrant activation of p53 observed in 
Mdm2Y487A/Y487A MEFs would be replicated in vivo, WT and Mdm2Y847A/Y487A mice were treated 
with a sublethal dose (5 Gy) of  irradiation. As expected, this dose of irradiation did not cause 
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any immediate disease or affect mortality in WT mice; however, in Mdm2Y847A/Y487A mice 5 Gy  
IR resulted in significant weight loss and 100% lethality by 22 days post treatment (Figure 2-27).  
To determine whether the observed phenotype is p53 dependent, Mdm2Y847A/Y487A mice 
with concomitant deletion of either one or both copies of p53 were similarly treated with 5 Gy  
IR. In contrast to Mdm2Y487A/Y487 mice with intact p53, both Mdm2Y847A/Y487A;p53+/- and 
Mdm2Y847A/Y487A;p53-/- mice were resistant to 5 Gy  IR treatment and demonstrated no significant 
changes in body weight or viability, indicating that the lethality observed in the Mdm2Y847A/Y487A 
mice was p53 dependent (Figure 2-28). While deletion of p53 can serve a protective function 
against the short term consequences associated with exposure to irradiation, including 
apoptosis and hematopoietic failure, we observed increased survival in Mdm2Y487A/Y487A;p53+/- 
mice compared to Mdm2Y487A/Y487A;p53-/- mice; this observation supports the idea that both too 
much p53, as in Mdm2Y487A/Y487A;p53+/+ mice, as well as too little p53, as in Mdm2Y487A/Y487A;p53-/- 
mice, can be deleterious (Donehower et al., 1992; Mendrysa et al., 2003).   
Gross examination 14 days after 5 Gy  IR treatment revealed a significantly smaller 
spleen in the Mdm2Y487A/Y487A mice (Figure 2-29). Additionally, analysis of the blood composition 
of WT and Mdm2Y487A/Y487A mice revealed that mutant mice have significantly lower levels of red 
blood cells and white blood cells following 5 Gy  IR treatment (Figure 2-30). The time of death 
following treatment, together with decreased splenic size and blood counts, is suggestive of 
hematopoietic failure as the ultimate cause of death in the irradiated mutant animals (Gudkov 
and Komarova, 2003; Mendrysa et al., 2003; Wang et al., 2011b).  
Histological examination indicated that both WT and Mdm2Y487A/Y487A mice have similarly 
low levels of p53 in the spleen prior to irradiation, and increased levels of p53 by 4 h after 
treatment with 5 Gy  IR (Figure 2-31 and Figure 2-32A). In contrast, in the presence of wild-
type Mdm2, p53 levels in the spleen return to near untreated levels by 24 h after 5 Gy  IR, 
while in the Mdm2Y487A/Y487A mutant dense areas with high p53 remain (Figure 2-31 and Figure 2-
41 
 
32A). Additional organs were analyzed to better examine the effect of the Mdm2Y487A mutation 
on the stress response in vivo; corresponding to observations in the spleen, p53 levels were 
relatively low and similar in the testes, intestine, and liver of untreated WT and Mdm2Y487A/Y487A 
mice (Figure 2-32B-D). Following 5 Gy  IR, however, p53 levels were higher in Mdm2Y487A/Y487A 
mice compared to WT mice at 4 h and 24 h post treatment in the intestine, and at 24 h in the 
testes; the liver is generally considered to be fairly radioresistant and did not demonstrate any 
changes in observed p53 (Figure 2-32B-D).  
To assess the effect of this observed increase in p53 protein on p53 activity, qRT-PCR 
of several p53 target genes, including p21, Mdm2, Bax, and TIGAR, in splenic and thymic tissue 
from WT and Mdm2Y487A/Y487A mice was performed. Following 5 Gy  IR, p53 activity is 
significantly higher in Mdm2Y487A/Y487A mice compared to the WT, as indicated by higher mRNA 
expression of p53 target genes, providing evidence that the higher p53 protein levels observed 
in Mdm2Y487A/Y487A mice are correlated with increased p53 activity (Figure 2-33 and Figure 2-34). 
The dynamics of the p53 stress response in the spleen and thymus were further examined by 
western blot; in response to 5 Gy  IR treatment, p21 was increased and maintained at a higher 
level in the Mdm2Y487A/Y487A mutant compared to the WT, further indicating that the observed 
accumulation of p53 protein is correlated with increased p53 activity (Figure 2-35). To infer the 
biological consequences of increased p53 levels and activity in the mouse, TUNEL staining was 
utilized to assess the level of apoptosis; in the spleen, corresponding to the increased p53 
levels and activity observed, increased levels of apoptosis were also observed in 
Mdm2Y487A/Y487A mice following irradiation (Figure 2-36). 
 
DISCUSSION 
Mdm2 has long been considered the gatekeeper of both p53 stability and activity, and as 
such, it is of critical importance that a proper understanding of Mdm2-mediated p53 regulation in 
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vivo exists.  While initially developed to further elucidate the various functions of the Mdm2 
RING finger domain in p53 regulation, the development and characterization of the Mdm2Y487A 
knock-in mouse model has shed new light on a number of potentially dogma shifting concepts in 
p53 regulation, including the necessity of Mdm2:MdmX heterodimerization, and the surprising 
apparent dispensability of robust Mdm2 E3 ligase activity for proper embryogenesis and 
development. The role of Mdm2:MdmX heterodimization has been moving to the forefront in 
recent years, but it has long been accepted that Mdm2 E3 ligase activity is an essential 
mechanism for Mdm2-mediated p53 regulation. With this in mind, the most unanticipated finding 
in the current study was that fully intact Mdm2 E3 ligase activity towards p53 is dispensable in 
vivo as demonstrated by the viability, and normal development and lifespan observed in 
Mdm2Y487A/Y487A mice. In vivo, the loss of Mdm2 E3 ligase activity resulted in increased 
stabilization of p53, but loss of E3 activity alone, without disruption of Mdm2:MdmX 
heterodimerization, was not sufficient to significantly increase p53 activity. Following activation 
of the p53 pathway, seemingly regardless of stimuli type, the loss of Mdm2 E3 ligase activity 
was correlated with a maintained increase in p53 activity, suggesting that while not necessary 
for regulating steady state levels of p53 activity, that the Mdm2 E3 ligase function is essential in 
controlling p53 abundance and activity once the p53 pathway has been activated.    
A number of recent knock-in mouse models, including MdmXΔRING, MdmXC462A, and 
Mdm2C462A, have implicated Mdm2:MdmX heterodimerization as an essential component of p53 
regulation, in large part due to the embryonic lethality observed when this interaction is 
disrupted (Huang et al., 2011; Itahana et al., 2007; Pant et al., 2011). In this regard, the 
Mdm2Y487A model provided vital complementary data, further pointing towards Mdm2:MdmX 
heterodimerization as the key to understanding p53 regulation. Uniquely, the Mdm2Y487A model 
allows for analysis of RING finger binding dynamics independent of Mdm2 E3 ubiquitin ligase 
activity.  Previous in vitro data, as well as our own in vitro study of Mdm2Y489A (Figure 2-17A and 
Figure 2-17C), supports a role for Mdm2:MdmX heterodimerization in improving, and at times 
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rescuing, Mdm2 E3 ligase activity; however, the study of this mutation in the corresponding 
knock-in mouse model described here suggests that Mdm2 E3 ligase activity is significantly 
disrupted even in the presence of Mdm2:MdmX heterodimerization (Okamoto et al., 2009; 
Poyurovsky et al., 2007; Uldrijan et al., 2007). The apparent discrepancy between Mdm2Y487A in 
vitro, which demonstrated near normal levels of p53 stabilization in the presence of MdmX 
(Figure 2-17B and Figure 2-17D), and in vivo, which demonstrated near, if not complete 
disruption of p53 degradation, serves as an additional example as to the importance of 
examining proteins at physiologically relevant levels. In fact, in vitro titration of MdmX in the 
presence of either mouse Mdm2Y487A or human Mdm2Y489A, demonstrated that at a 1:1 ratio 
coexpression of MdmX reduced p53 stabilization, but when MdmX was expressed at a 1:5 or 
1:10 ratio with Mdm2, correlating to ratios previously observed in human cells (Wang et al., 
2009; Wang et al., 2007), coexpression of MdmX with mutant Mdm2 had a greatly diminished 
effect on p53 stability (Figure 2-37).  
The E3 inactive status of the Mdm2Y487A mutant in vivo allows for us to demonstrate that 
the function of Mdm2:MdmX interaction goes beyond E3 ligase activity; following activation with 
4-OHT, p53ER levels are similarly reduced in both the presence and absence of MdmX (Figure 
2-18), indicating that under unstressed conditions the degradation of p53 by Mdm2 does not 
require MdmX binding. While Mdm2:MdmX heterodimerization is not necessary for p53 
degradation, loss of Mdm2:MdmX interaction, either from deletion of MdmX 
(Mdm2Y487A/Y487A;MdmX-/-;p53ER/-) or mutation of Mdm2 (Mdm2C462A/C462A;MdmX+/+;p53ER/-),  
correlated with increased p53 transcriptional activity (Figure 2-14A-D) as well as increased 
mRNA levels of p53 itself (Figure 2-14E). Moreover, in the presence of Mdm2:MdmX 
heterodimerization, p53:p300 binding is reduced, corresponding to lower levels of acetylated 
p53, and providing a potential mechanism through which  the Mdm2:MdmX heterodimer is 
functioning to regulate p53 activity (Figure 2-15). Collectively, these data suggest that the 
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Mdm2:MdmX heterodimer not only plays a critical role in suppressing p53 transcriptional activity, 
but also a role in regulating p53 protein levels independent of Mdm2 E3 ligase function.    
While demonstrated to be required for proper embryogenesis, and correlated with the 
regulation of p53 stability and activity, the mechanism through which Mdm2:MdmX 
heterodimerization is functioning in these roles remains poorly understood. However, in concert 
with existing mouse models we believe our data supports the following model: Under 
unstressed conditions the Mdm2:MdmX heterodimer inhibits p300-mediated acetylation of p53, 
and in concert with direct binding of the Mdm2:MdmX heterodimer to the p53 transactivation 
domain this is sufficient to regulate p53 activity, but following stress and the subsequent post-
translational modifications to p53, Mdm2, and MdmX, p53 levels and activity are increased. 
Once p53 has been activated, direct binding of Mdm2 and MdmX is no longer sufficient to 
control p53, and Mdm2 E3 ubiquitin ligase activity becomes critical in allowing for recovery from 
activation of the p53-mediated stress response (Figure 2-38). 
In addition to implications on the role of Mdm2 E3 ligase activity in the regulation of p53 
stability, the Mdm2Y487A mouse model has also provided additional insight into Mdm2 
degradation. Despite efficient disruption of p53 degradation, the Mdm2Y487A mutant protein did 
not affect the rate of degradation of Mdm2 itself, suggesting that Mdm2 autodegradation is not 
the primary mechanism for Mdm2 regulation in vivo. This same phenomenon was observed in 
the Mdm2C462A knock-in mouse; however, the location of the Mdm2C462A mutation in the RING 
finger domain made it likely to affect its protein structure, and with that potentially affect Mdm2 
degradation (Itahana et al., 2007). Due to the location of the Y487 amino acid residue of Mdm2, 
C-terminal of the RING finger domain, it should not disrupt zinc coordination, and proper folding 
and the structure of the RING domain should remain intact (Figure 2-13). While the E3 ligase 
responsible for Mdm2 degradation in vivo is yet to be identified, this model provides further 
evidence that under physiological conditions autoubiquitination is not the primary mechanism for 
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Mdm2 degradation. Additional research into the regulation of Mdm2 stability, and identification 
of E3 ubiquitin ligases with specificity for Mdm2 are important ventures to be explored. 
Due to the high rate of p53 mutation, deletion, and misregulation in many cancers, in 
theory, the p53 pathway is an attractive drug target; however, effective therapeutics utilizing this 
pathway are not yet found in the clinic (Danovi et al., 2004; Hainaut et al., 1997; Momand et al., 
1998; Wade et al., 2013). As brought to light by our study, the basic understanding of p53 
regulation in vivo is continuing to evolve. The key findings from this study have important clinical 
implications, as a number of drugs targeting the Mdm2-p53 pathway, including Nutlin-3a, were 
developed to target Mdm2:p53 interaction and/or Mdm2-mediated ubiquitination of p53 
(Vassilev et al., 2004; Wade et al., 2013). Moving forward, our data suggests that drugs 
disrupting Mdm2-mediated ubiquitination of p53 used in isolation may not be sufficient to 
significantly activate p53. Another possible therapeutic route to explore more thoroughly is the 
development of compounds targeting the interaction of Mdm2 and MdmX. Along with a number 
of recent knock-in mouse models, the Mdm2Y487A mouse points to the significance of 
Mdm2:MdmX heterodimerization in both p53 stability and activity, and thus disruption of this 
interaction may be a potent therapeutic target. Despite the apparent necessity of Mdm2:MdmX 
interaction in proper p53 regulation, a comprehensive understanding of the mechanism through 
which this dimer is functioning in this role remains to be explored. Focused study of the 
interaction between Mdm2 and p53 at physiological levels has provided additional insight into 
both p53 and Mdm2 regulation, which will allow for more effective application of therapeutics 
targeting this pathway, as well as additional targets for the development of new drugs.  
 
EXPERIMENTAL PROCEDURES 
Generation of Mdm2Y487A Knock-in Mice 
Murine 129/Sv genomic DNA containing the last six exons (7–12) of Mdm2 was a gift 
from Dr. Guillermina Lozano (University of Texas, M.D. Anderson Cancer Center). The targeting 
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vector was constructed in a PGK neo vector. A tyrosine to alanine substitution (TAC to GCA) 
was introduced in codon 487 using site-directed mutagenesis. The final construct was 
sequenced using overlapping primers. Electroporation of 129/Sv-derived AB2.2 ES cells was 
performed by the UNC Animal Models Core Facility. DNA isolated from G418-resistant ES 
colonies were further confirmed for the presence of the Y487A substitution by PCR amplification 
of genomic DNA using primers flanking exon 12, followed by sequencing. Two positive clones 
were injected into C57BL/6 blastocysts, and the blastocysts were transferred into 
pseudopregnant female recipients. The resulting chimeric males were mated with C57BL/6 
females, and germline transmission was confirmed by PCR analysis and DNA sequencing. 
Following germline transmission of the Mdm2Y487A mutation, Mdm2Y487A/+ mice were mated with 
Ella-Cre transgenic mice (Jackson Laboratories, stock number 003724) to excise the 
neomycin selection marker. The resulting mice were backcrossed to C57BL/6 for five 
generations to yield ~97% C57BL/6 genetic background. Mice were bred and maintained strictly 
under protocols 10-045 and 13-044 approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill Animal Care Facility. 
 
Mouse Breeding, Genotyping and Experiments 
PCR was utilized to identify the Mdm2Y487A mutation using primers for the wild type 
(m305wF 5’- TTATTGAAGGACTATTGGAAGTGTACCTCA-3’; mY487A-W-R-4 5’- 
GTGAGCAGGTCAGCTAGTTGAAGTA-3’) and mutant (m305wF; mY487A-M-R-1 5’- 
TTGTGAGCAGGTCAGCTAGTTGAATGC-3’) alleles.  The MdmX null mice were a gift from Dr. 
Guillermina Lozano (University of Texas, M.D. Anderson Cancer Center).  The p53 null mice 
were purchased from The Jackson Laboratory (stock number 002101).  PCR primers for wild-
type (p53-X7, 5′-GGATGGTGGTATACTCAGAGCC-3′; p53-X6, 5′-
ACAGCGTGGTGGTACCTTAT-3′) and mutant (p53-X7; NEO18.5, 5′-
TCCTCGTGCTTTACGGTATC-3′) p53 alleles were described by The Jackson Laboratory. 
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p53ERTAM knock-in mice were a gift from Dr. Gerard Evan (University of Cambridge, UK) and 
genotyping of the p53ERTAM alleles was performed as described previously (Christophorou et al., 
2005). 
At 5.5 to 8.5 weeks of age, mice were treated with 5 Gy  irradiation (Mark I Model 68-1 
Cesium –137 Irradiator) at a dose rate of 1.89 Gy/minute. For survival studies following 
irradiation, mice were monitored and weighed every other day, and moribund mice were 
humanely euthanized. Mouse tissue was fixed in formalin for histopathology and snap frozen in 
liquid nitrogen for protein extraction. 
 
Cell Culture 
Primary MEF cells were cultured in a 37°C incubator with 5% CO2, and 3% O2 in DMEM 
supplied with 10% FBS and penicillin (100 IU/ml)/streptomycin (100 μg/ml).  For activation 
of p53ERTAM, 100 nM 4-hydroxytamoxifen (Sigma) dissolved in 100% ethanol was added to the 
culture medium. MEF cells were treated as indicated with 25 J/m2 UV, 5 nM actinomycin D (Act 
D), 1 μM doxorubicin (Dox), or 5 Gy  IR. 
 
Protein Analysis 
Mouse monoclonal Mdm2 (2A10, Calbiochem), MdmX (MdmX-82, Sigma), p53 (NCL-
505, Leica), phospho-p53 (Ser15, Cell Signaling), acetyl-p53 (Lys320, Cell Signaling), actin 
(MAB1501, Chemicon International), and goat polyclonal p21 (C-19; Santa Cruz) antibodies 
were purchased commercially. Rabbit polyclonal antibody to p21 was a gift from Dr. Yue Xiong 
(UNC-Chapel Hill). Mouse monoclonal antibody to MdmX (7A8) was a gift from Dr. Jiandong 
Chen (University of South Florida).  MEF cells were lysed in 0.1% NP-40 buffer for 
immunoprecipitation and 0.5% NP-40 buffer for straight western blotting. Tissue was lysed in 
tissue lysis buffer (0.2% Triton X-100, 0.3% NP-40). Procedures and conditions for 
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immunoprecipitation and immunoblotting were described previously (Itahana et al., 2003). 
Protein cross-linking was performed prior to p53 immunoprecipitation as described previously 
(Clegg et al., 2012; Itahana et al., 2007). The half-life of p53 and Mdm2 protein was measured 
by treating cells with cycloheximide (100 μg/ml) for the indicated length of time, followed by lysis 
in 2% SDS lysis buffer. The protein level was analyzed by western blotting, and the intensity of 
the bands in the linear range of exposure was quantified by densitometry. Subcellular 
fractionation was performed using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo 
Scientific) according to manufacturer’s instructions. 
 
Quantitative Real-time PCR 
Total RNA was isolated using an RNeasy Kit (Qiagen) and cDNA was synthesized using 
SuperScript III (Invitrogen).  qRT-PCR was performed with SYBR green master mix (Applied 
Biosystems) using the7900HT Fast Real-Time PCR System (Applied Biosystems) according to 
manufacturer instructions. Data was collected and exported with SDS 2.2.2 software. Relative 
expression was calculated using GAPDH or Actin as an internal control as indicated. Primers 
used were as follows: Mdm2, 5’CCA ACCATCGACTTCCAGCAGCATT3’ and 5’GAT 
TGGCTGTCTGCACACTGGG3’; p21,  5’CCTGGTGATGTCCGACCTG3’ and 5’CCATGAGCG 
CATCGCAATC3’; APAF1, 5’CGGTGAAGGTGTGGAATGTCATTACCG3’ and 5’GGATTTCTCC 
ATTGTCATCTCCAGTTGC3’; Bax, 5’GGACAGCAATATGGAGCTGCAGAGG3’ and 5’GGAGG 
AAGTCCAGTGTCCAGCC3’; TIGAR, 5’CGATCTCACGAGGACTAAGCAGACC3’ and 5’GCCA 
AAGAGCTTTCCAAACCGCTGC3’; GAPDH, 5’AGGTCGGTGTGAACGGATTTG3’ and 5’TGTA 
GACCATGTAGTTGAGGTCA3’; Actin, 5’CCACAGCTGAGAGGGAAATCGTGC 3’ and 5’CCAG 
AGCAGTAATCTCCTTCTGCATCC3’, p53, 5’ATGGAGGAGCCGCAGTCAGATC3’ and 
5’CCATTGTTCAATATCGTCCGGG3’. 
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Immunohistochemistry and TUNEL staining 
Tissue from Mdm2+/+ and Mdm2Y487A/Y487A mice was harvested and fixed in 10% formalin 
for 24 h. Five micrometer sections were stained by immunohistochemistry for p53 (NCL-p53-
CM5p, Leica Biosystems) and DAB staining. TUNEL staining for apoptosis was performed using 
the Apoptag Peroxidase In Situ Apoptosis Detection Kit (Millipore) according to manufacturer’s 
instructions. Stained tissue was analyzed using an Olympus IX-81 microscope fitted with a 
SPOT camera and software. 
 
Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism 4 Software (GraphPad 
Software, San Diego, CA). For lifespan analysis and irradiation experiments a Kaplan-Meier 
survival curve was carried out. A two-tailed unpaired t-test analysis was utilized to compare 
mRNA levels in qRT-PCR experiments.3 
 
  
                                               
3 We thank Dale Cowley from UNC Animal Models Core Facility for developing the Mdm2 
knock-in mice, and Everardo Macias, Yizhou He, Yong Liu, Hengming Ke, and Patrick Leslie for 
their helpful advice and technical assistance. We are indebted to Jiandong Chen, Yue Xiong, 
Guillermina (Gigi) Lozano, Gerard Evan, Aart Jochemsen, Fabiola Moretti, Stephen Jones, 
Moshe Oren, and Zhi-Min Yuan for their generosity in sharing reagents. This research was 
supported by grants from the National Institutes of Health (CA127770 and CA167637) to Y.Z. 
and UNC Genetics and Molecular Biology Training Grant to L.T. This research was also 
supported by grants from the Leukemia and Lymphoma Society, American Cancer Society, and 
NSFC from China to Y.Z. 
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Figure 2-1. Schematic Representation of the Mdm2 Targeting Vector. 
Solid boxes represent regions of vector homology to the target locus; thick numbered boxes 
represent the last six Mdm2 exons. Triangles indicate the presence and orientation of loxP sites. 
Site directed mutagenesis was used to introduce the Tyr-to-Ala mutation at the 487 amino acid 
residue. 
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A B 
Figure 2-2. DNA Analysis of Mdm2Y487A Mutation. 
 
A) PCR amplification of genomic DNA isolated from toe snips of mouse pups was utilized for 
genotyping. 
 
B) Sequencing analysis of genomic DNA isolate from offspring of Mdm2Y487A/+ heterozygous 
matings. DNA was PCR amplified (primer location indicated with arrows in A) and then 
sequenced by the UNC Genome Analysis Facility. 
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Figure 2-3. Mdm2Y487A/Y487A Mice Are Viable. 
A 
B 
A) Observed and expected birth ratios from Mdm2Y487A/+ intercrosses; total of 302 offspring 
observed. 
 
B) Mdm2+/+, Mdm2Y487A/+, and Mdm2Y487A/Y487A male and female mice were observed weekly 
for activity and viability. Kaplan-Meier survival curve is shown. 
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A 
B 
Figure 2-4. Mdm2Y487A Mutation Correlates with Slightly Lower Body Weight. 
A) Mdm2+/+, Mdm2Y487A/+, and Mdm2Y487A/Y487A male mice were weighed and observed weekly. 
Data represent means +/- SEM. 
 
B) Mdm2+/+, Mdm2Y487A/+, and Mdm2Y487A/Y487A female mice were weighed and observed 
weekly. Data represent means +/- SEM. 
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Figure 2-5. p53 Stability in MEFs and Mouse Tissue. 
Early passage Mdm2+/+ (WT), Mdm2Y487A/+ (487/+), and Mdm2Y487A/Y487A (487/487) MEF cell 
lysates, and lysates from the spleen, thymus, testes, and brain of 8-week old Mdm2+/+ (WT) 
and Mdm2Y487A/Y487A (487/487) mice were analyzed by western blotting for p53 and p21 
levels. Actin was used as a loading control. 
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Figure 2-6. Mdm2Y487A Cannot Effectively Degrade p53. 
A) Early passage Mdm2+/+ and Mdm2Y487A/Y487A MEFs were treated with 100 µg/mL 
cycloheximide and harvested using SDS lysis buffer at the time points indicated.  The levels 
of p53 and actin were analyzed by western blotting.  The amount of p53 was quantified by 
densiometry, normalized to the level of actin, and plotted. 
 
B) Levels of p53ER were measured and analyzed as in A. 
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Figure 2-7. p53 is Degraded in a Proteasome Dependent Manner. 
Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) MEFs were treated with 25 µM MG-132 for 5 
hours as indicated.  Lysates were collected and the level of p53 was analyzed by western 
blotting. 
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Figure 2-8. Binding Properties of Mdm2Y487A. 
A) MEFs were immunoprecipitated (IP) and immunoblotted with the indicated antibodies. 
Loading represents 1% of total cell lysate utilized for IP.  Mdm2C462A/C462A;p53-/- MEFs were 
utilized as a negative control for Mdm2:MdmX binding. 
 
B) MEFs were immunoprecipitated and immunoblotted with the indicated antibodies as in A, 
MdmX-/-;p53ER/- MEFs were utilized as a negative control for Mdm2:MdmX binding.  
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Figure 2-9. Mdm2Y487A Attenuates MdmX Degradation. 
A) Early passage Mdm2+/+ and Mdm2Y487A/Y487A MEFs were treated with 100 µg/mL 
cycloheximide and harvested using SDS lysis buffer at the time points indicated.  The levels 
of MdmX and actin were analyzed by western blotting.  The amount of MdmX was quantified 
by densiometry, normalized to the level of actin, and plotted. 
 
B) The degradation of MdmX in Mdm2+/+;p53ER/- and Mdm2Y487A/Y487A;p53ER/-  MEFs was 
analyzed as in (A).  
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Figure 2-10. Protein Subcellular Localization. 
Immunofluorescent staining of endogenous p53 (A), MdmX (B), or MdmX (C) in Mdm2+/+ and 
Mdm2Y487A/Y487A MEFs. DAPI was utilized as a nuclear marker. 
 
D) Cytoplasmic and nuclear extracts were separated in Mdm2+/+ and Mdm2Y487A/Y487A MEFs 
by fractionation and p53, MdmX, and Mdm2 levels in each fraction were analyzed by western 
blotting. PARP was used as a nuclear marker and β-tubulin was used as a cytoplasmic 
marker. 
D 
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Figure 2-11. In Vivo Loss of Mdm2 E3 Ligase Activity Does Not Affect Mdm2 Degradation. 
A) Early passage WT and Mdm2Y487A/Y487A MEFs were treated with 100 µg/mL cycloheximide 
and harvested using SDS lysis buffer at the time points indicated.  The levels of Mdm2 and 
actin were analyzed by western blotting.  The amount of Mdm2 was quantified by 
densiometry, normalized to the level of actin, and plotted. 
 
B) The degradation of Mdm2 in Mdm2+/+;p53ER/- and Mdm2Y487A/Y487A;p53ER/- MEFs was 
analyzed as in A. 
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Figure 2-12. Mdm2 is Degraded in a Proteasome Dependent Manner. 
Mdm2+/+;p53-/-, Mdm2Y487A/Y487A;p53-/-, and Mdm2C462A/C462A;p53-/- MEFs were treated with 25 
µM MG-132 for 8 hours as indicated.  Lysates were collected and the level of Mdm2 was 
analyzed by western blotting. Actin was used as a loading control. 
62 
 
 
 
  
Figure 2-13. Crystal Structure of Mdm2:MdmX Heterodimer. 
Crystal structure of the human Mdm2:MdmX RING domain interaction.  Arrows indicate the 
location of human Mdm2 Y489 (mouse Mdm2 Y487) and human Mdm2 C464 (mouse Mdm2 
C462) amino acid residues.  Mdm2 is depicted in green, MdmX in orange, and zinc ions are 
represented as red balls. 
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Figure 2-14. Mdm2:MdmX Heterodimerization Decreases p53 Activity. 
A) mRNA levels of Mdm2 in Mdm2+/+;MdmX+/+;p53ER/- (WT), Mdm2Y487A/Y487A;MdmX+/+;p53ER/- 
(487/487), Mdm2Y487A/Y487A;MdmX-/-;p53ER/- (487/487;MdmX-/-), and 
Mdm2C462A/C462A;MdmX+/+;p53ER/- (462/462) MEFs after 100 nM 4-OHT treatment was 
measured by qRT-PCR.  All samples were analyzed in triplicate. Data are means +/- SD 
normalized to Actin. 
mRNA levels of p21 (B), Apaf1 (C), Bax (D) and p53 (E) were analyzed via qRT-PCR as in 
(A). 
 
64 
 
  
A B 
Figure 2-15. Mdm2:MdmX Heterodimerization Attenuates p53 Acetylation. 
A) Mdm2+/+;p53ER/-, Mdm2Y487A/Y487A;p53ER/-, and Mdm2C462A/C462A;p53ER/- MEFs were incubated 
with 4-OHT for 4 h, harvested and analyzed by western blotting.  Actin was used as a 
loading control. 
 
B) Mdm2+/+;p53ER/-, Mdm2Y487A/Y487A;p53ER/-, and Mdm2C462A/C462A;p53ER/- MEF lysates were 
cross-linked and then immunoprecipitated and immunoblotted as indicated. Cells were 
incubated with 4-OHT for 4 h prior to cross-linking. 
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Figure 2-16. Mdm2:MdmX Heterodimer Reduces p53 Protein Stabilization. 
Mdm2+/+;MdmX+/+;p53ER/-, Mdm2Y487A/Y487A;MdmX+/+;p53ER/-, Mdm2Y487A/Y487A;MdmX-/-;p53ER/-, 
and Mdm2C462A/C462A;MdmX+/+;p53ER/- MEFs were treated with 100 nM 4-OHT for the indicated 
times.  Cell lysates were harvested and analyzed by western blotting. 
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Figure 2-17. In Vitro, Coexpression of MdmX with Mdm2Y487A or Mdm2Y489A Restores p53 
Degradation. 
A) U2OS cells were transfected with myc-hp53, myc-hMdmX, FLAG-hMdm2, and/or FLAG-
hMdm2Y489A (FLAG-Y489A) as indicated and analyzed by western blotting.  
 
B) U2OS cells were transfected with myc-mp53, myc-mMdmX, FLAG-mMdm2, and/or FLAG-
mY487A as indicated and analyzed by western blotting.  
 
C) U2OS cells were transfected as in (A) and the effect of transfected human Mdm2, mutant 
Mdm2Y489A, and/or MdmX as indicated on endogenous p53 was analyzed by western 
blotting. 
 
D) U2OS cells were transfected as in (B) and the effect of transfected  mouse Mdm2, mutant 
Mdm2Y487A, and/or MdmX as indicated on endogenous p53 was analyzed by western 
blotting. 
 
C D 
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Figure 2-18. Deletion of MdmX Does Not Affect p53 Stability. 
A) Mdm2+/+;MdmX+/+;p53ER/-  MEFs were treated with 100 nM 4-OHT for the indicated times.  
Cell lysates were harvested and analyzed by western blotting. 
 
B) Mdm2+/+;MdmX-/-; p53ER/- MEFs were treated with 100 nM 4-OHT for the indicated times.  
Cell lysates were harvested and analyzed by western blotting. 
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Figure 2-19. Loss of E3 Ligase Activity Exacerbates p53 Response to UV. 
(A, B, C, D, and E) Expression of p53 target genes, p21 (A), Mdm2 (B), Bax (C), Apaf1 (D), 
and TIGAR (E) in Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) MEFs was measured by qRT-
PCR after 25 J/m2 UV treatment as indicated.  Untreated (Untd) MEFs were used as a 
control. All samples were analyzed in triplicate minimally.  Data are means +/- SD normalized 
to GAPDH. 
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Figure 2-20. Loss of E3 Ligase Activity Exacerbates the p53 Stress Response. 
(A, B, C, D, and E) Expression of p53 target genes, p21 (A), Mdm2 (B), Bax (C), Apaf1 (D), 
and TIGAR (E) in Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) MEFs was measured by qRT-
PCR after 5 Gy -irradiation, 1 µM doxorubicin, or 5 nM actinomycin D treatment as 
indicated.  All samples were analyzed in triplicate minimally.  Data are means +/- SD 
normalized to GAPDH. Untreated (Untd) MEFs were used as a control. All samples were 
analyzed in triplicate minimally.  Data are means +/- SD normalized to GAPDH. 
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Figure 2-21. DNA Damage Induced Phospho-p53 Levels Maintained at High Levels in 
Mdm2Y487A/Y487A MEFs. 
A) WT MEFs were treated with 5 Gy X-ray irradiation, cell lysates were collected at the 
indicated time points and analyzed by western blotting. 
 
B) Mdm2Y487A/Y487A MEFs were treated, collected, and analyzed as in (A). 
 
C)WT and Mdm2Y487A/Y487A MEFs were treated with 25 J/m2 UV irradiation, cell lysates were 
collected at the indicated time points and analyzed by western blotting. 
 
D) WT and Mdm2Y487A/Y487A MEFs were treated with 1 µM doxorubicin, cell lysates were 
collected at the indicated time points and analyzed by western blotting. Drug was removed 4 
h after treatment. 
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Figure 2-22. Mdm2Y487A Cannot Degrade p53 After Stress. 
A, B, and C) DNA damage induced by UV (A) or doxorubicin (B), or ribosomal stress induced 
by Actinomycin D (C) was utilized to activate the p53 pathway in Mdm2+/+ and 
Mdm2Y487A/Y487A MEFs, cell lysates were collected at the indicated time points and analyzed 
by western blotting.  In (A) and (B) drug was removed after 4 h of treatment. 
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Figure 2-23. Effect of Stress on p53 Transcription. 
p53 mRNA levels in Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) MEFs was measured by 
qRT-PCR following exposure to 25 J/m2 UV irradiation, 5 Gy -irradiation, 1 µM doxorubicin, 
or 5 nM actinomycin D treatment as indicated.  All samples were analyzed in triplicate.  Data 
are fold induction of means +/- SD normalized to GAPDH. 
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Figure 2-24. Effect of Mdm2Y487A on the Cell Cycle. 
Mdm2+/+ and Mdm2Y487A/Y487A MEFs were left untreated (D), treated with 5 Gy IR (E), or 5 nM 
Act D (F) for 24 h followed by staining with propidium iodide, and then analyzed by flow 
cytometry. 
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Figure 2-25. Mdm2Y487A/Y487A MEFs Demonstrate Decreased Cell Survival After  
Doxorubicin Treatment. 
Mdm2+/+ and Mdm2Y487A/Y487A MEFs were harvested and counted after 24 h or 48 h of 1 µM 
Dox treatment as indicated. Survival was calculated relative to the number of cells observed 
in untreated samples at the same time points. 
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Figure 2-26. Oxidative Stress of Cell Culture Increases p53 Stability and Slows Cell 
Growth. 
A 
B 
A) Mdm2+/+ and Mdm2Y487A/Y487A MEFs were harvested at 3% O2 or 20% O2 as indicated and 
then cultured at 3% O2 or 20% O2 as indicated. Cells treated with 50 J/m
2 UV were used as a 
positive control for p53 stabilization and activity. Cell lysates were harvested after 24 h of 
culturing and analyzed by western blotting.  
 
B and C) Mdm2+/+ and Mdm2Y487A/Y487A MEFs cultured in 20% or 3% O2 as indicated were 
trypsinized, stained with trypan blue, and counted in triplicate using a BioRad TC10 
Automated Cell Counter.  Data represent means of total cells (B) or surviving cells (C) as 
determined by trypan blue staining. 
 
C 
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Figure 2-27. Mdm2Y487A/Y487A Mice Demonstrate Increased Radiosensitivity. 
A) Kaplan-Meier survival curve for Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) female mice 
treated with a sublethal dose (5 Gy) of -irradiation. Mice were between 5.5 and 8.5 weeks 
old at the time of treatment. 
 
B) Mdm2+/+ (WT), and Mdm2Y487A/Y487A (487/487) female mice were treated with a sublethal 
dose (5 Gy) of -irradiation and observed and weighed every other day.  Mice were between 
5.5 and 8.5 weeks old at time of treatment.  Data are means +/- SD. 
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Figure 2-28. Radiosensitivity in Mdm2Y487A/Y487A Mice is p53 Dependent. 
A) Kaplan-Meier survival curve for Mdm2Y487A/Y487A;p53+/+ (487/487;p53+/+), 
Mdm2Y487A/Y487A;p53+/- (487/487;p53+/-), and Mdm2Y487A/Y487A;p53-/- (487/487;p53-/-) male mice 
treated with a sublethal dose (5 Gy) of -irradiation.  Mice were between 6.5 and 7.5 weeks 
old at time of treatment. 
 
B) Mdm2Y487A/Y487A;p53+/+(487/487;p53+/+), Mdm2Y487A/Y487A;p53+/- (487/487;p53+/-), and 
Mdm2Y487A/Y487A;p53-/- (487/487;p53-/-) male mice were treated with a sublethal dose (5 Gy) of 
-irradiation and observed and weighed every other day.  Mice were between 6.5 and 7.5 
weeks old at time of treatment.  Data are means +/- SD. 
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Figure 2-29. Sublethal Irradiation Reduces Spleen Size in Mdm2Y487A/Y487A Mice. 
A) Representative gross histology of Mdm2+/+ and Mdm2Y487A/Y487A spleens of 6.5 week old 
male mice either untreated or treated with 5 Gy -irradiation as indicated; spleens were 
collected 14 days after treatment. 
 
B) Spleens of Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) 6.5 week old male mice either 
untreated or treated with 5 Gy -irradiation were harvested 14 days after treatment.  Data 
represent means of spleen weight relative to overall body weight +/- SD.  Untreated 
Mdm2Y487A/Y487A N=4, treated Mdm2Y487A/Y487A N=3, untreated Mdm2+/+ N=3, treated Mdm2+/+ 
N=3.   
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Figure 2-30. Sublethal Irradiation Reduces Blood Count in Mdm2Y487A/Y487A Mice. 
Red blood cell and white blood cell counts taken from Mdm2+/+ and Mdm2Y487A/Y487A mice 14 
days after 5 Gy -IR treatment.  Data are means of mutant mice relative to WT mice +/- SD.  
Untreated Mdm2Y487A/Y487A N=3, treated Mdm2Y487A/Y487A N=3, untreated Mdm2+/+ N=4, treated 
Mdm2+/+ N=3.   
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Figure 2-31. Immunohistochemistry of p53 in Splenic Tissue. 
Immunohistochemistry staining for p53 in splenic tissue from Mdm2+/+ and Mdm2Y487A/Y487A 
mice left untreated or after 5 Gy -irradiation as indicated (20X magnification). 
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Figure 2-32. Mdm2Y487A/Y487A Mice Demonstrate Increased Levels of p53 After Irradiation. 
Tissue from the spleen (A), testes (B), intestine (C), and liver (D) of Mdm2+/+ and 
Mdm2Y487A/Y487A mice was stained by immunohistochemistry for p53 after 5 Gy -irradiation as 
indicated (20X magnification for A, B, and D; 40X magnification for C). Mice were 27 to 30 
weeks old at the time of treatment. 
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Figure 2-33. Higher p53 Activity Observed in the Spleen of Mdm2Y487A/Y487A Mice After 
Irradiation. 
mRNA levels of the p53 target genes p21 (A), Mdm2 (B), Bax (C), and TIGAR (D) in the 
spleen of Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) female mice either untreated or 
treated with 5 Gy -irradiation as indicated was measured by qRT-PCR. Mice were between 
11 and 18 weeks old at time of treatment. All samples were analyzed in triplicate.  Data are 
means +/- SD normalized to GAPDH. 
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Figure 2-34. Higher p53 Activity Observed in the Thymus of Mdm2Y487A/Y487A Mice After 
Irradiation. 
mRNA levels of the p53 target genes p21 (A), Mdm2 (B), Bax (C), and TIGAR (D) in the 
thymus of Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) female mice either untreated or 
treated with 5 Gy -irradiation as indicated was measured by qRT-PCR. Mice were between 
11 and 18 weeks old at time of treatment. All samples were analyzed in triplicate.  Data are 
means +/- SD normalized to GAPDH. 
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Figure 2-35. Mdm2Y487A/Y487A Mice Demonstrate Increased p21 After Irradiation. 
A) Fourteen-week old Mdm2+/+ and Mdm2Y487A/Y487A female mice were treated with a 
sublethal dose (5 Gy) of -irradiation. Splenic tissue harvested at the indicated time points 
was analyzed by western blotting for p21 levels. Actin was used as a loading control. 
 
B) Thirteen-week old Mdm2+/+ and Mdm2Y487A/Y487A male mice were irradiated and protein 
from the thymus harvested at the indicated time points was analyzed by western blotting for 
p21 levels. Actin was used as a loading control. 
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Figure 2-36. Increased Apoptosis is Observed in the Spleen of Mdm2Y487A/Y487A Mice After 
Irradiation. 
Splenic tissue from Mdm2+/+ and Mdm2Y487A/Y487A mice left untreated or after 5 Gy -irradiation 
as indicated stained for apoptosis by Apoptag Peroxidase In Situ Apoptosis Detection Kit 
(20X magnification). 
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Figure 2-37. Mdm2:MdmX Ratio Affects p53 Stability. 
A) U2OS cells were transfected with FLAG-hp53, FLAG-hY489A, and myc-hMdmX as 
indicated and analyzed by western blotting. 
 
B) U2OS cells were transfected with FLAG-mp53, FLAG-mY487A, and myc-mMdmX as in 
(A) and analyzed by western blotting. 
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Mdm2:MdmX 
heterodimerization is sufficient 
to control p53 activity 
Mdm2 E3 ligase activity is  
required to reduce p53  
levels and activity 
Figure 2-38. Mdm2:MdmX Heterodimer Regulation of p53. 
Model depicting Mdm2:MdmX heterodimer regulation of p53 before and after activation of the 
p53 stress response pathway. 
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3. CHAPTER 3. THE ANAPHASE-PROMOTING COMPLEX IS AN E3 UBIQUITIN LIGASE 
FOR MDM24 
 
INTRODUCTION 
Mdm2 is well characterized as the major negative regulator of the tumor suppressor p53 
(Manfredi, 2010; Momand et al., 1992; Oliner et al., 1993). The C-terminus RING finger domain 
of Mdm2 confers its intrinsic E3 ubiquitin ligase activity, which promotes the ubiquitination and 
degradation of p53 (Brooks and Gu, 2006; Haupt et al., 1997; Honda et al., 1997; Kubbutat et 
al., 1997). In addition to promoting p53 degradation, Mdm2 is also a transcriptional target of p53, 
forming a regulatory feedback loop between Mdm2 and p53 to maintain cellular homeostasis 
(Barak et al., 1993; Honda et al., 1997; Juven et al., 1993; Lahav, 2008; Perry et al., 1993). The 
importance of Mdm2 in proper p53 regulation makes the understanding of its own regulation of 
critical concern.  
In order for the Mdm2-p53 feedback loop to function properly, tight regulation of Mdm2 
degradation is essential. Previous in vitro and overexpression studies have demonstrated that 
Mdm2 regulates its own degradation by autoubiquitination, targeting itself for proteasome-
mediated degradation (Fang et al., 2000; Honda and Yasuda, 2000). However, the advent and 
characterization of Mdm2C462A/C462A knock-in mice have challenged the dogma of Mdm2 
autoubiquitination. In Mdm2C462A/C462A mouse embryonic fibroblasts (MEFs), p53 degradation is 
blocked, while mutant Mdm2C462A protein is degraded as rapidly as the wild type, indicating that 
                                               
4 This chapter is adapted from a research article published in Cell Cycle. The concept of the 
project was developed by Yizhou He and Yanping Zhang. Tae-Hyung Kim performed the half-
life assays for p53 and Mdm2. Yoko Itahana performed the in vitro and in vivo ubiquitination 
assays. I performed the MG132 assay. All other experiments were performed by Yizhou He. 
The manuscript was written by myself and Yizhou He and finalized by Yanping Zhang. The 
original citation is as follows: Yizhou He, Laura Tollini, Tae-Hyung Kim, Yoko Itahana, and 
Yanping Zhang. (2014) The Anaphase-Promoting Complex/Cyclosome is an E3 Ubiquitin 
Ligase for Mdm2. Cell Cycle 13(13). 
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Mdm2 E3 ubiquitin ligase activity is not required for its own degradation when endogenously 
expressed (Clegg et al., 2008; Itahana et al., 2007). The observation of Mdm2 degradation 
independent of its own intrinsic E3 ubiquitin ligase activity suggests that other E3 ubiquitin 
ligases may function to regulate Mdm2 stability in vivo.  
In light of the in vivo data suggesting that Mdm2 does not auto-ubiquitinate as previously 
believed, the potential for an outside E3 ubiquitin ligase to function in Mdm2 regulation has been 
more expressly studied. The Cullin1/β-TRCP E3 ubiquitin ligase complex was identified to 
interact with Mdm2 and this interaction is demonstrated to lead to poly-ubiquitination and 
degradation of Mdm2 (Inuzuka et al., 2010). However, the regulatory dynamics of 
Mdm2:Cullin1-βTRCP interaction suggests that this interaction only occurs following DNA 
damage. Furthermore, knockdown of Cullin1-βTRCP does not block p53 activation upon stress; 
instead, it affected the regulation of Mdm2 and p53 during the recovery of cells to basal 
conditions following exposure to stress (Inuzuka et al., 2010). More recently, NEDD4-1 was 
biochemically identified to contribute to the regulation of Mdm2 protein stability in cells by 
functioning as an E3 ligase (Xu et al., 2014), however, NEDD4-1 catalyzes the formation of 
K63-type polyubiquitin chains on Mdm2, distinct from the K48-type polyubiquitin chains 
mediated by the Mdm2/MdmX complex. Notably, K63-type polyubiquitination by NEDD4-1 
competes with K48-type polyubiquitination of Mdm2 in cells, and as a result, NEDD4-1-
mediated ubiquitination stabilizes Mdm2. Our study was designed to identify additional E3 
ubiquitin ligases responsible for the regulation of Mdm2 stability under physiological conditions, 
and particularly in the absence of cellular stress.  
 
RESULTS AND DISCUSSION 
Mdm2 E3 Ubiquitin Ligase Function is Dispensable for Mdm2 Self-Degradation  
To examine the role of Mdm2 E3 ligase function in Mdm2 self-degradation in vivo, we 
compared degradation dynamics of Mdm2 in MEFs expressing wild type (WT) Mdm2 or E3 
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ligase inactive mutant Mdm2. We generated two Mdm2 knock-in mouse models with inactivated 
Mdm2 E3 ubiquitin ligase activity towards p53: the Mdm2Y487A (corresponding to human 
Mdm2Y489A) (unpublished data) and Mdm2C462A (corresponding to human Mdm2C464A) (Itahana et 
al., 2007). Both of the mutated Mdm2 genes are under control of the native promoter and hence 
promote physiological levels of Mdm2 expression. While both the Mdm2Y487A and Mdm2C462A 
proteins display disrupted E3 ubiquitin ligase activity for p53, the mechanism of disruption in 
each of these mutants is unique. The Mdm2Y487A mutation is C-terminal of the RING domain, 
in a region previously demonstrated to be critical for Mdm2 E3 ubiquitin ligase activity towards 
p53, however, this mutant retains an intact RING domain (Uldrijan et al., 2007). In contrast, the 
Mdm2C462A mutation affects one of the four critical cysteine residues responsible for 
maintaining the RING domain structure; disruption of the Mdm2 RING domain structure results 
in the loss of E3 ubiquitin ligase activity (Uldrijan et al., 2007). Because the Mdm2C462A mutation 
results in early embryonic lethality in homozygous mice, we crossed Mdm2C462A/+ mice with mice 
expressing inducible p53ERTAM (p53ER hereafter); the inducible nature of the p53ER fusion 
protein allows for generation of mice and MEFs with inactive p53. The addition of 4-
Hydroxytamoxifen (4-OHT) activates p53ER to allow for transactivation of Mdm2 and the study 
of Mdm2 dynamics in the otherwise lethal Mdm2C462A background. In the presence of 4-OHT, 
the half-life of p53ER was approximately 30 minutes, and the half-life of Mdm2 approximately 15 
minutes in Mdm2+/+;p53ER/- MEFs (Figure 3-1A). The disruption of Mdm2 E3 ligase activity, 
greatly extended the half-life of p53ER, as observed in Mdm2Y487A/Y487A;p53ER/- and 
Mdm2C462A/C462A;p53ER/- MEFs (Figures 3-1B and 3-1C). These results support previous findings 
and indicate that in vivo the Mdm2Y487A and Mdm2C462A mutant proteins have indeed lost E3 
ubiquitin ligase activity for p53 degradation.  
To evaluate the importance of Mdm2 E3 ligase function in the degradation of Mdm2 itself, 
we assessed the half-life of Mdm2 in Mdm2+/+;p53ER/-, Mdm2Y487A/Y487A;p53ER/-, and 
Mdm2C462A/C462A;p53ER/- MEFs. Despite disrupting p53 degradation, Mdm2Y487A and Mdm2C462A 
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protein itself was degraded normally when compared with WT Mdm2 (Figure 3-1). Furthermore, 
treatment with the proteasome inhibitor MG132 led to similar stabilization of WT Mdm2, 
Mdm2Y487A, and Mdm2C462A (Figure 3-2A), suggesting that each of these proteins is degraded at 
a similar rate, in a proteasome dependent manner. To eliminate the possible aberrant effect of 
p53ER on transcriptional regulation of Mdm2, Mdm2+/+;p53-/-, Mdm2Y487A/Y487A;p53-/-, and 
Mdm2C462A/C462A;p53-/- mice were generated, and MEFs were isolated and similarly subjected to 
MG132 treatment. As observed in the p53ER/- genetic background, in the absence of p53, a 
similar level of Mdm2 stabilization was observed regardless of the E3 ligase status (Figure 3-
2B). These results suggest that while Mdm2 E3 ligase function is necessary for the degradation 
of p53, under physiological conditions, it is dispensable for its own degradation through the 
proteasome-dependent pathway.  
In light of the normal, proteasome-dependent Mdm2 degradation dynamics observed in 
Mdm2 E3 inactive MEFs, we postulated that an alternative E3 ubiquitin ligase(s) is responsible 
for Mdm2 degradation under physiological conditions. To test this hypothesis, we used an in 
vitro ubiquitin ligase assay to assess the E3 ubiquitin ligase activity of HeLa cell lysate towards 
bacterial purified Mdm2 protein. Consistent with previous studies (Fang et al., 2000), and similar 
to most other RING finger domain-containing proteins that confer E3 ligase activity (Deshaies 
and Joazeiro, 2009), purified WT Mdm2 protein demonstrated intrinsic autoubiquitination activity 
in the in vitro ubiquitin ligase assay; in contrast, Mdm2C464A mutant protein does not demonstrate 
intrinsic autoubiquitination activity (Figure 3-3A). Interestingly, following addition of HeLa cell 
lysate to the Mdm2C464A protein reaction samples, strong polyubiquitin chain formation was 
observed (Figure 3-3A). The ability for Mdm2C464A to be polyubiquitinated in the presence of 
HeLa cell lysate suggests that an E3 ubiquitin ligase(s) capable of polyubiquitinating Mdm2 is 
present in the lysate. To rule out the possibility that WT Mdm2 present in the HeLa lysate is 
responsible for the observed polyubiquitination of Mdm2C464A, we assessed polyubiquitin chain 
formation in cell lysate isolated from WT, Mdm2+/+;p53-/- and Mdm2-/-;p53-/- MEFs. Polyubiquitin 
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chain formation in WT, Mdm2+/+;p53-/- and Mdm2-/-;p53-/- MEF cell lysate occurs at similar levels 
(Figure 3-3B), indicating that a component in the MEF cell lysates, independent of both Mdm2 
and p53, is capable of promoting Mdm2 polyubiquitination. 
We then tested if this polyubiquitin chain formation is dependent on E1 and E2 supplied 
in vitro by individually removing each of these reaction components. The polyubiquitin chain 
formation is dependent on E2 supplied in vitro, but to our surprise the HeLa cell lysates 
contained sufficient E1 ubiquitin activating enzyme to support the in vitro ubiquitination reaction 
(Figure 3-3C). Furthermore, we found that the E3 ubiquitin ligase activity from HeLa cell lysates 
is diminished in the presence of SDS, providing further evidence that an enzymatic activity in 
the HeLa lysate is essential for the observed polyubiquitin chain formation (Figure 3-3D). 
 
Mdm2 Interacts with APC2 
Previous studies have indicated that Mdm2 protein levels oscillate with the cell cycle (Gu 
et al., 2003; Inuzuka et al., 2010). Accordingly, we also found that in WT and p53-/- MEFs 
synchronized by serum starvation Mdm2 protein levels oscillated in a manner correlated to 
cyclin B1 oscillations (Figures 3-4A and 3-4B). Similar results were also observed in U2OS cells 
synchronized with serum starvation (Figure 3-4C), and HeLa and HCT116/p53-/- cells 
synchronized by double thymidine block (Figures 3-4D and 3-4E). Together, these results 
suggest that Mdm2 levels might be regulated during mitosis, presumably by a member of the 
Cullin family E3 ubiquitin ligases, in a manner similar to cyclin B1. Furthermore, the observed 
oscillation of Mdm2 in p53 null cells suggests that this manner of Mdm2 regulation is p53-
independent.  
To test the possibility that a Cullin family E3 ubiquitin ligase is responsible for the 
ubiquitination and degradation of Mdm2, we first determined the binding affinity of Cullin family 
E3 ubiquitin ligases with Mdm2 via immunoprecipitation. As shown in Figures 3-5A, Mdm2 
interacted with co-overexpressed Cullin1, providing additional support for previous studies 
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characterizing Cullin1:Mdm2 binding (Inuzuka et al., 2010). Additionally, we observed Mdm2 
interaction with APC2, a scaffold subunit of APC/C, a multi-subunit E3 ubiquitin ligase complex 
that controls the degradation of many proteins involved in cell cycle regulation (Figure 2C). Most 
APC/C substrates oscillate their protein levels through the cell cycle and function to control 
multiple cell cycle transitions, including the metaphase-anaphase transition and mitotic exit 
(Peters, 2006; Thornton et al., 2006; Yu, 2007). We confirmed APC2:Mdm2 interaction with 
reciprocal immunoprecipitation of ectopically expressed proteins (Figures 3-5B and 3-5C), as 
well as with immunoprecipitation of endogenous Mdm2 in 293T and H1299 cells (Figures 3-5D). 
293T and H1299 cells express similar levels of APC2, but different levels of Mdm2, which 
allowed for correlation of the levels of Mdm2 with the levels of APC2 being co-
immunoprecipitated.  
 
APC2 is Important for Mdm2 Degradation 
To test if APC/C is a physiological E3 ubiquitin ligase for Mdm2, we knocked down 
APC2, the scaffolding subunit in the APC/C E3 ubiquitin ligase complex, in human tumor cell 
lines. Knockdown of APC2 by siRNA in both U2OS (p53 positive) and HCT116/p53-/- (p53 
negative) cells led to accumulation of Mdm2 (Figures 3-6A and 3-6B), as well as extension of 
Mdm2 protein half-life (Figures 3-7). To further rule out the possibility that the increase in Mdm2 
is due to increased transcription of Mdm2 rather than decreased degradation, we generated 
stable cell lines expressing GFP-tagged WT Mdm2 (GFP-Mdm2) or GFP-tagged Mdm2C464A 
mutant under the control of the CMV promoter. As shown in Figures 3-6C, knockdown of APC2 
by siRNA led to a strong accumulation of ectopic GFP-tagged Mdm2, indicating that the 
accumulation of Mdm2 is independent of transcriptional regulation. More importantly, 
knockdown of APC2 by siRNA also led to a strong accumulation of ectopic GFP-tagged 
Mdm2C464A, which suggests that the Mdm2 accumulation observed following downregulation of 
APC2 is independent of Mdm2 E3 ligase activity (Figures 3-6D). Disruption of proteasome-
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mediate degradation by MG132 treatment resulted in an accumulation of Mdm2 in U2OS cells 
transfected with a control knockdown (siCtrl), but did not further stabilize Mdm2 in cells with 
knocked down APC2 (siAPC2) , which demonstrated high level of Mdm2 prior to MG132 
treatment (Figures 3-6E). Together, these results indicate that APC2 is important for Mdm2 
degradation in a manner independent of p53 status and Mdm2 transcriptional regulation.    
 
APC2 is Important for Stress Induced p53 Stabilization and Activation 
Because Mdm2 is the primary regulator for p53, mechanisms functioning to regulate 
Mdm2 will inevitably affect p53 function as well. To investigate the functional connection of 
APC2 with p53 activity, we examined the effect of downregulation of APC2 on p53 induced 
growth inhibition. We generated MEF cells with stable knockdown of APC2 in WT and p53-/- 
genetic backgrounds. Stable knockdown of APC2 in the WT, but not p53-/- background, 
corresponded to an ability to undergo an increased number of passages, and a higher number 
of cells displaying flattened and enlarged morphology, indicative of senescence. Assessment of 
-galactosidase activity was utilized to determine whether the flattened and enlarged MEF cells 
were indeed senescent. MEFs with APC2 knocked down exhibited significantly weaker activity 
of senescence-associated -galactosidase than did control cells (Figure 3-8A). Additionally, 
quantitative analysis indicated that APC2 knockdown decreased the percentage of senescent 
cells by more than half (Figure 3-8A). We then analyzed the effect of APC2 knockdown on p53 
activity by examining p53-dependent transcription using a p21-luciferase assay. As shown in 
Figure 3-8B, p53-dependent activation of the p21 promoter was greatly reduced by knockdown 
of APC2.   
To investigate the role of APC2 in the p53 stress response, we knocked down APC2 by 
shRNA in WT MEFs and examined cell survival following exposure to ultraviolet (UV) radiation. 
While APC2 knockdown did not affect cell survival under unstressed conditions, it increased cell 
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survival upon UV induced DNA damage (Figure 3-8C). This increase in cell survival was 
attenuated when Mdm2-p53 interaction was disrupted by Nutlin-3 (Figure 3-8D), suggesting that 
the effect of APC2 on cell survival following UV radiation is p53-dependent.  
To determine whether APC2 might regulate stress-induced p53 expression, siRNA was 
used to knock down APC2 in U2OS cells, followed by treatment with genotoxic agents to 
challenge the cells. Indeed, downregulation of APC2 substantially reduced the level of p53 
induced by the DNA damaging agents, as observed following treatment with UV (Figure 3-9A) 
and doxorubicin (Figure 3-9B), as well as in response to ribosomal stress, as induced by 
actinomycin D (Figure 3-9C). These results indicate that APC2 plays an important role in p53 
stabilization in response to genotoxic stress.  
 
APC2 Downregulation Correlates with Cancer Development 
To further investigate the physiological relevance of APC2 regulation of Mdm2, we 
assessed the expression levels of APC2 and Mdm2 in various cancer cells. An inverse 
correlation between the levels of APC2 and Mdm2 was observed in the eight cell lines 
examined; more specifically, JAR and SJSA cells expressed very low levels of APC2, and 
conversely very high levels of Mdm2 compared to HepG2, MCF7, HeLa, A375, U2OS and 
H1299 cells which expressed higher levels of APC2 and lower levels of Mdm2 (Figure 3-10). To 
investigate the clinical relevance of variation in APC2 expression, we interrogated available 
tumor data sets for APC2. Based on an analysis of the Oncomine database 
(http://www.oncomine.com), APC2 mRNA levels were revealed to be significantly decreased in 
breast, liver, and lymphocyte cancer tissue compared to that observed in corresponding normal 
tissue (Figure 3-11). Investigation of breast, ovarian, lung, thyroid, liver, and renal cancer tissue 
in The Cancer Genome Atlas (TCGA) also revealed that APC2 gene copy number was 
decreased compared to the gene copy number observed in normal tissue (Figure 3-12). The 
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decreased levels of APC2 mRNA and APC2 gene copy number in a variety of cancer types 
suggest that APC2 may be clinically relevant in the development or progression of cancer.  
Here, we report that Mdm2 protein stability is regulated by the APC/C E3 ubiquitin ligase 
complex through APC2:Mdm2 interaction. Various biochemical analyses, including protein 
binding and degradation assays, as well as functional assays, clearly identify Mdm2 as a 
substrate of APC2. Depletion of APC2 results in increased levels of Mdm2, which in turn leads 
to attenuation of stress-induced p53 stabilization, and increased cell survival.  
Mitotic inhibitors that activate the spindle assembly checkpoint by perturbing microtubule 
function are commonly used in the treatment of breast, ovarian, and lung cancers (Montero et 
al., 2005), however, as activation of the spindle assembly checkpoint does not suppress APC/C 
activity completely, it is believed that inhibitors directly targeting APC/C could provide a better 
therapeutic method for inducing mitotic arrest (Zeng et al., 2010). In contrast, our study 
suggests that inhibition of APC/C can result in oncogenic consequences due to accumulation of 
Mdm2, and the resulting inactivation of p53. In light of the suppressive effect of APC/C inhibition 
on p53 activity as a consequence of Mdm2 stabilization, the prospect of pharmacologic 
inhibition of APC/C as an anti-cancer therapeutic is potentially hindered. The observation that 
APC2 depletion effectively stabilizes Mdm2,and leads to inhibition of p53 activation, indicates 
that cautious consideration of the p53 status must be taken prior to use of cancer treatments 
targeting APC/C related pathways.  
 
EXPERIMENTAL PROCEDURES 
Cell Culture, Transfection 
All cells were cultured at 37°C, and 5% CO2 in DMEM supplemented with 10% FBS, 100 
U/mL penicillin, and 100 ug/mL streptomycin. DNA transfections were carried out using the 
calcium phosphate method (Sambrook and Russell, 2006) and Fugene-6 (Roche) according to 
manufacturer’s instructions.  
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Double Thymidine Block synchronization 
Cells were cultured with 2 mM thymidine for 19 hours, washed once with 1 X PBS, 
incubated with fresh media without addition of thymidine, and then 2 mM thymidine was added 
back 8 hours later. After 16 hours of incubation, cells were washed once with 1 X PBS, and 
incubated in fresh media without thymidine addition. Cells were collected every 2 hours and 
analyzed by western blotting.  
 
DNA Plasmids, siRNA and Lenti-viral based shRNA 
All cloned constructs were confirmed by DNA sequencing. siRNA duplexes targeting 
APC2 (5’-AACGATCTGCAGGCCAACATC-3’), and nonspecific control siRNA (5’-
CAGUCGCGUU UGCGACUGG-3’) were manufactured by Dharmacon. Stealth siRNAs 
targeting APC2 (HSS121004, HSS179082, HSS179083) were manufactured by Invitrogen. 
Lenti-viral based shRNA clones were purchased commercially from Open Biosystems (pLKO.1 
shRNA sets RMM4534-NM_175300). siRNA transfections were performed with RNAiMax 
(Invitrogen # 13778) according to the manufacturer’s instructions 48 hours before additional 
treatments. 
 
SDS-PAGE and Western Blotting 
Cells were lysed in 0.5% NP-40 lysis buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 0.5% 
 NP-40, 50 mM NaF, 1 mM NaVO3, 1 mM DTT, 1 mM PMSF, 1x Protease inhibitor cocktail), 
lysates were resolved on a 12.5% polyacrylamide gel and transferred onto a 0.45 µM 
nitrocellulose membrane. Membranes were blocked for at least 30 minutes in blocking buffer 
(PBS with 0.1% Tween-20 and 5% nonfat dried milk). Membranes were incubated overnight in 
primary antibody diluted in blocking buffer, incubated for 1-2 hours in secondary HRP-
conjugated antibody diluted in block buffer, and exposed after incubation in Supersignal West 
Pico or Dura (Pierce) for 5 minutes.  
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IP-Western Blotting 
MEF cells were lysed in 0.5% NP-40 lysis buffer. The lysates were pre-cleared with 
Sepharose CL4B beads (Sigma) for 30 min and then immunoprecipitated with the specified 
antibody overnight at 4°C, followed by incubation with protein A/G beads (Pierce) for 2 hours at 
4°C. The beads were washed four times with cold 0.5% NP-40 lysis buffer, and analyzed by 
SDS-PAGE and western blotting. 
 
Half-life assay 
Cells were treated with cycloheximide (100-150 μg/mL) for the indicated length of time 
and then harvested using 1X SDS lysis buffer (50mM Tris-HCl, pH 7.5, 0.5mM EDTA, 1% SDS, 
and 1 mM DTT). Mdm2 and p53 levels were analyzed by western blotting, and the intensity of 
the bands in the linear range of exposure was quantified by densitometry and normalized to 
Actin using ImageJ. 
 
Beta-Gal staining 
Beta-Gal staining was done with Senescence β-Galactosidase Staining Kit (Cell 
Signaling #9860) according to the manufacturer’s instructions. 
 
Luciferase assay 
Beta-Gal staining was done with Dual-Light® Luciferase & β-Galactosidase Reporter 
Gene Assay System (Life technologies #T1004) according to the manufacturer’s instructions. 
 
Antibodies 
Rabbit anti-APC2 antibody was kindly provided by Dr. Yue Xiong (UNC at Chapel Hill). 
HA (12CA5), myc (9E10), Mdm2 (2A10), and Mdm2 (4B11) antibodies were made from the 
culture medium of the hybridoma cell line.  The following antibodies were purchased 
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commercially: Actin (Chemicon #MAB1501R), hp53 (DO-1 Labvision AB-6 #MS-187 - P), mp53 
(Leica # NCL-p53-505), FLAG (M2 Sigma #F3165). Anti-UB (Covance #PRB-268C), Cyclin B1 
(GNS1 Santa Cruz #sc0245).5 
 
  
                                               
5 We thank Yue Xiong for providing APC2 antibody and expression plasmid, and Michael 
Emanuele for helpful discussion. This research was supported by grants from the National 
Institutes of Health (CA127770 and CA167637) and from the American Cancer Society to Y.Z. 
and the UNC Genetics and Molecular Biology (GMB) Training grant to L.T. Y.Z. is a recipient of 
a Career Award in Biomedical Science from the Burroughs Wellcome Fund, a Howard Temin 
Award from the National Cancer Institute, and a Scholar Award from the Leukemia & 
Lymphoma Society.  
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Figure 3-1. Mdm2 E3 Ubiquitin Ligase Function is Dispensable for Mdm2 Self-
Degradation Under Physiological Conditions. 
A) Mdm2+/+;p53ER/- MEFs were treated with 100 nM 4OHT for 24 hours before treatment with 
150 ug/mL cycloheximide. Cell lysates were collected at the indicated times following 
cycloheximide treatment and p53ER and Mdm2 levels were analyzed by western blot. Actin 
was used as a loading control.  
 
B) Mdm2Y487A/Y487A;p53ER/- MEFs were treated and analyzed as described in (A). 
 
C) Mdm2C462A/C462A;p53ER/- MEFs were treated and analyzed as in (A). 
 
B 
A 
C 
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Figure 3-2. Mdm2 Degradation is Mediated by the Proteasome. 
A) Mdm2+/+;p53ER/-, Mdm2Y487A/Y487A;p53ER/-, and Mdm2C462A/C462A;p53ER/- MEFs were treated 
with 25 uM MG132 for 8 hours as indicated.  Mdm2 levels were analyzed by western blot. 
Actin was used as a loading control.  
 
B) Mdm2+/+;p53-/-, Mdm2Y487A/Y487A;p53-/-, and Mdm2C462A/C462A;p53-/- MEFs were treated and 
analyzed as in (A).  
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Figure 3-3. Mdm2 E3 Ligase Activity is Not Necessary for Mdm2 Degradation. 
A) Bacterial purified GST, GST tagged wild type Mdm2 (WT), and GST tagged Mdm2C464A 
(C464A) bound to glutathione beads was incubated with E1, E2 and Ubiquitin (Ub) with or 
without the addition of HeLa cell lysate for 1 hour at 37˚C as indicated. Ubiquitin was 
analyzed by western blot. 
 
B) Bacterial purified GST tagged Mdm2C464A (C464A), E1, E2 and Ubiquitin (Ub) was 
incubated as (A) with cell lysate from wild type (WT), Mdm2+/+;p53-/-(p53-/-), or Mdm2-/-;p53-/-
MEFs as indicated. 
 
C) E1, E2, Ubiquitin (Ub), and bacterial purified GST tagged Mdm2C464A bound to glutathione 
beads were incubated with HeLa cell lysate as indicated for 1 hour at 37˚C.  Glutathione 
beads were washed three times with 1XPBS and ubiquitin was analyzed by western blot. 
 
D) E1, E2, Ubiquitin (Ub), and bacterial purified GST tagged wild type Mdm2 (WT), or 
Mdm2C464A bound to glutathione beads were incubated with HeLa cell lysate in the lysis 
buffer indicated, analyzed as in (C). 
 
 
D) 
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Figure 3-4. Oscillation of Mdm2 Correlates with Cyclin B1. 
A) Mdm2+/+ (WT) MEFs were incubated with DMEM with 0.1% FBS for 72 hours for serum 
starvation, media was then replaced with fresh DMEM with 10% FBS. Cells were harvested 
at the indicated time points and analyzed by western blot.  Actin was used as a loading 
control. 
 
B) p53-/- MEFs were treated, harvested, and analyzed as in (A). 
C) U2OS cells were synchronized with serum starvation, harvested, and analyzed as in (A). 
 
D and E) HeLa cells (D) and HCT116/p53-/- cells (E) were synchronized with a double 
thymidine block, harvested, and analyzed as in (A). 
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Figure 3-5. Mdm2 Interacts with APC2. 
A) 293T cells were transfected with FLAG-tagged Mdm2 together with HA-tagged Cullin1 
(Cul1), Cullin2 (Cul2), APC2, Cullin3 (Cul3), Cullin4A (Cul4A), or Cullin5 (Cul5) as indicated. 
Cell lysate was immunoprecipitated and immunoblotted with the indicated antibodies. Input 
represents 4% of total cell lysate utilized for IP.  
 
B) 293T cells were transfected as indicated. Cell lysate was immunoprecipitated with anti-
FLAG and immunoblotted as indicated. Input represents 4% of total cell lysate utilized for IP.  
 
C) 293T cells were transfected as indicated. Cell lysate was immunoprecipitated with anti-
Myc antibody and immunoblotted as indicated. Input represents 4% of total cell lysate utilized 
for IP. 
 
D) 293T cell and H1299 cell lysates were immunoprecipitated with anti-Mdm2 antibody and 
immunoblotted as indicated.  Input represents 2% of total cell lysate utilized for IP.  H1299 
cells, with a low level of Mdm2, were used as a negative control. 
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Figure 3-6. APC2 is Important for Mdm2 Degradation. 
A) U2OS cells were transfected with control siRNA (Ctrl) or APC2 siRNA (APC2) for 72 
hours. Cell lysates were analyzed by western blotting for Mdm2 and APC2.  Actin was used 
as a loading control. 
 
B) HCT116/p53-/- cells were transfected, harvested, and analyzed as in (A). 
 
C) Clonal stable cell line stably expressing a GFP-Mdm2 fusion protein under the control of 
CMV promoter in U2OS cells were transfected, harvested, and analyzed as in (A).  
 
D) Clonal stable cell line stably expressing a GFP-Mdm2C464A fusion protein under the 
control of CMV promoter in U2OS cells were transfected, harvested, and analyzed as in (A).  
 
E) U2OS cells were transfected with control siRNA (si-Ctrl) or APC2 siRNA (si-APC2) for 24 
hours, cells were then split and 25 uM MG132 was added 48 hours later. Cells were 
collected at indicated time after MG132 treatment and analyzed by western blot.  Actin was 
used as a loading control.  
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Figure 3-7. Knockdown of APC2 Stabilizes Mdm2. 
A) U2OS cells were transfected with control siRNA (si-Ctrl) or APC2 siRNA (si-APC2) for 24 
hours, cells were split and 150 ug/mL cycloheximide was added 48 hours later. Cell lysates 
were collected at the indicated times following cycloheximide treatment and Mdm2 levels 
were analyzed by western blot. Actin was used as a loading control. Mdm2 levels were 
measured by densitometry, normalized to Actin, and plotted. 
 
B) HCT116/p53-/- cells were transfected with control siRNA (si-Ctrl) or APC2 siRNA (si-
APC2) for 24 hours, cells were split and 150 ug/ml cycloheximide was added 48 hours later. 
Cells were collected and analyzed as in (A). 
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Figure 3-8. APC2 is Important for Stress Induced p53 Stabilization and Activation. 
A) WT and Mdm2+/+;p53-/- MEFs infected with non-specific (sh-NS) or APC2 (sh-APC2) 
Lentiviral based shRNA were cultured for 12 passages. Cells were stained with beta-gal and 
the percentage of beta-gal positive cells was quantified and plotted. 
 
B) U2OS cells were transiently transfected with control siRNA (si-Ctrl) or APC2 siRNA (si-
APC2) for 24 hours, cells were split, followed by transfection with a pGL3-Basic luciferase 
reporter plasmid containing the wild-type p21 promoter (p21-Luc) or an empty vector 
(Vector).  Cells were collected 24 hours later and assayed for luciferase activity. Co-
transfection with LacZ under control of the CMV promoter was utilized as a transfection 
control. 
 
C) WT MEFs infected with non-specific (sh-NS) or APC2 (sh-APC2) Lentiviral based shRNA 
were treated with different dosages of UV as indicated. Cells were collected 24 hours after 
UV treatment, stained with trypan blue, and counted to determine cell survival.  
 
D) WT MEFs infected with non-specific (sh-NS) or APC2 (sh-APC2) Lentiviral based shRNA 
were treated with 40 J/m2 UV and 8 uM Nutlin-3. Cells were collected 24 hours after 
treatment, stained with trypan blue, and counted to determine cell survival. 
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Figure 3-9. Knockdown of APC2 Decreases p53 Stabilization After Stress. 
A) U2OS cells were transfected with control siRNA (si-Ctrl) or APC2 siRNA (si-APC2) for 24 
hours, cells were split, and treated with 15 J/m2 UV 48 hours later. Cells were collected at the 
indicated time points after UV treatment, and analyzed for Mdm2 and p53 by western blot.  
Actin was used as a loading control. p53 levels were measured by densitometry, normalized 
to actin, and plotted. 
 
B) U2OS cells were transfected with siRNA as in (A), treated with 0.5 ug/mL doxorubicin, 
collected and analyzed as in (A). 
 
C) U2OS cells were transfected with siRNA as in (A), treated with 5 nM actinomycin D, 
collected and analyzed as in (A). 
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Figure 3-10. APC2 and Mdm2 Levels Inversely Correlate in Cancer Cell Lines. 
Western blot was used to assess APC2 and Mdm2 in JAR, HepG2, SJSA, MCF7, HeLa, 
A375, U2OS and H1299 cancer cell lines.  Actin was used as a loading control. 
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Figure 3-11. APC2 mRNA Levels are Lower in Cancer. 
mRNA microarray data for APC2  in Invasive Breast Carcinoma (Finak Breast), Ductal Breast 
Carcinoma (Richardson Breast 2), Liver cancer with Cirrhosis (Mas Liver), and Unspecified 
Peripheral T-Cell Lymphoma (Piccaluga Lymphoma) as indicated. Data was obtained from 
Oncomine. 
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Figure 3-12. APC2 Gene Copy Number is Lower in Cancer. 
TCGA gene copy number data for APC2 in Breast, Ovarian, Lung, Thyroid, Liver, and Renal 
cancer as indicated.  Data was obtained from Oncomine. 
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4. CHAPTER 4. DISCUSSION AND FUTURE DIRECTIONS 
The Evolving Mechanism of Mdm2:MdmX Regulation of p53 
Despite decades of extensive study, our understanding of p53 function and regulation is 
continually evolving. The development of novel research techniques and animal models, 
including the Mdm2Y487A knock-in mouse model described here, along with a continued 
concerted effort to understand p53 in the context of disease, leaves us better poised to 
effectively target this overarching pathway therapeutically.   
The generation and characterization of the Mdm2Y487A knock-in mouse model has further 
expanded our current knowledge of p53 regulation in vivo, and shed light on a few key 
questions in the field such as the role of Mdm2 E3 ligase activity in the degradation of p53, 
MdmX, and itself, and the functional importance of Mdm2:MdmX heterodimerization in p53 
regulation. Furthermore, the development of the Mdm2Y487A model provides a useful tool for 
future in-depth studies exploring the regulatory dynamics of the p53 pathway.  
Mdm2 E3 ubiquitin ligase function is classically considered to be a critical component of 
Mdm2-mediated regulation of p53 stability, making it all the more surprising that loss of this 
function in Mdm2Y487A/Y487A mice did not have an aberrant effect on embryogenesis or 
development (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997). In contrast with 
previous dogma, the Mdm2Y487A model suggests that robust Mdm2-mediated ubiquitination and 
degradation of p53 is not required to sufficiently control p53 activity during embryogenesis or 
under basal conditions in the adult mouse.  Furthermore, the viability of mice homozygous for 
the Mdm2Y487A mutation allowed for the study of the effect of this mutation on wild-type p53; 
many of the in vivo models disrupting Mdm2 and MdmX mediated regulation of p53 result in 
early embryonic lethality, which necessitates the use of hypomorphic, inducible, or 
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transcriptionally dead p53 and introduces another confounding variable in data interpretation 
(Christophorou et al., 2005; Huang et al., 2011; Itahana et al., 2007; Pant et al., 2011).  
While the Mdm2Y487A model suggests that Mdm2 E3 ligase activity is not essential for the 
level of p53 regulation required for proper embryogenesis and development, in response to 
various stimuli, loss of Mdm2 E3 ligase activity correlates with increased p53 activity, and 
maintained high levels of p53 protein, making apparent the essential nature of this Mdm2 
function in modulating the magnitude of p53 activation and facilitating recovery following 
activation of the p53 pathway. Although the misregulation of p53 in the Mdm2C462A knock-in 
model indicated that Mdm2:p53 binding independent of Mdm2 RING domain function cannot 
efficiently regulate p53, the viability and apparent normalcy of Mdm2Y487A/Y487A mice served to 
implicate the MdmX binding function, rather than E3 ubiquitin ligase function, of the RING finger 
domain as essential for regulation of p53 activity (Clegg et al., 2012; Itahana et al., 2007).  
While disruption of Mdm2:MdmX heterodimerization, as in Mdm2C462A, MdmXC462A and 
MdmXΔRING, results in early embryonic lethality in the mouse, the normalcy of Mdm2Y487A mice, 
which maintain Mdm2:MdmX interaction, provided important complementary data to support the 
seemingly essential nature of Mdm2:MdmX interaction in p53 regulation (Huang et al., 2011; 
Itahana et al., 2007; Pant et al., 2011). Current in vitro study from a number of groups has 
implicated enhancement of Mdm2 E3 ubiquitin ligase activity as the basis for the functional 
significance of Mdm2:MdmX heterodimerization (Linares et al., 2003; Singh et al., 2007; Uldrijan 
et al., 2007; Wade and Wahl, 2009). Although it has not been exhaustively proven that the 
Mdm2Y487A mutation fully disrupts Mdm2 E3 ligase activity for p53 in vivo, in contrast with in vitro 
studies of Mdm2Y487A and Mdm2Y489A, the corresponding mutation in human, interaction of 
endogenous MdmX with Mdm2Y487A cannot restore effective degradation of p53 in MEFs. Of 
note, in vivo disruption of Mdm2:MdmX interaction did not affect p53 ubiquitination or stability in 
MdmXΔRING MEFs, further supporting a functional role for Mdm2:MdmX interaction independent 
of E3 ubiquitin ligase activity (Pant et al., 2011). While the Mdm2Y487A and MdmXΔRING models 
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suggest that Mdm2:MdmX interaction does not promote Mdm2 E3 ubiquitin ligase activity for 
p53 in vivo, these models further implicate Mdm2 E3 ligase function in the degradation of MdmX 
in vivo; disruption of either Mdm2 E3 ligase activity or Mdm2:MdmX interaction increases MdmX 
stabilization (Huang et al., 2011; Pant et al., 2011). 
In addition to affecting p53 and MdmX stability, Mdm2:MdmX heterodimerization has 
also been proposed to play a role in the stability of Mdm2. Mdm2:MdmX heterodimer formation 
is proposed to enhance Mdm2 stability through promoting the preferential degradation of MdmX, 
compared to that observed in Mdm2 monomers or Mdm2:Mdm2 homodimers (Linke et al., 
2008). Lending support to this protective role for Mdm2:MdmX interaction in Mdm2 stability, 
disruption of Mdm2:MdmX heterodimerization in MdmXΔRING MEFs correlates with decreased 
stability of Mdm2 following DNA damage (Pant et al., 2011). On the other hand, disruption of 
Mdm2:MdmX heterodimerization may also correlate with lower levels of Mdm2 ubiquitination, as 
observed in MdmXC462A MEFs, directly conflicting with the hypothesis that Mdm2:MdmX 
interaction serves to stabilize Mdm2 (Huang et al., 2011). Mdm2 ubiquitination and degradation 
is well characterized to be mediated through its own E3 ubiquitin ligase activity; Mdm2 
autoubiquitination serves as the mechanistic crux connecting enhanced Mdm2 stability, 
Mdm2:MdmX interaction, and preferential ubiquitination of MdmX (Fang et al., 2000; Honda and 
Yasuda, 2000; Stommel and Wahl, 2004). The advent of the Mdm2C462A knock-in mouse model 
called into question the necessity of autoubiquitination for Mdm2 degradation in vivo, and the 
generation of the Mdm2Y487A knock-in mouse provides additional insight into the regulation of 
Mdm2 protein stability at endogenous levels (Itahana et al., 2007). Similar to Mdm2C462A, 
Mdm2Y487A disrupts p53 degradation, while maintaining normal Mdm2 degradation dynamics 
(Itahana et al., 2007). The ability for two structurally unique Mdm2 mutations to disrupt p53 
ubiquitination and degradation without affecting the ubiquitination of Mdm2 itself, further 
supports the likelihood that an alternative E3 ubiquitin ligase functions in Mdm2 regulation 
(Clegg et al., 2008). Although Mdm2 autoubiquitination does not appear to be the primary 
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mechanism for Mdm2 degradation in vivo, our identification and characterization of APC2 as an 
E3 ubiquitin ligase capable of regulating Mdm2 stability has expanded our understanding of 
Mdm2 degradation dynamics.    
While a growing body of data, including that discussed here, suggests that Mdm2:MdmX 
heterodimerization is important, if not necessary, in the regulation of basal p53 activity, the 
specific mechanism behind this regulatory role remains largely unknown. Of note, despite loss 
of Mdm2 E3 ubiquitin ligase activity resulting in increased p53 stability in Mdm2Y487A/Y487A MEFs, 
significantly higher p53 activity is not observed until p53 is further stimulated. The disconnect 
between p53 stability and p53 activity in Mdm2Y487A/Y487A MEFs, in contrast to the high levels of 
p53 accumulation and activity observed in Mdm2C462A/C462A, points to an additional level of 
regulation. While both the Mdm2Y487A and Mdm2C462A mutants lack Mdm2 E3 ubiquitin ligase 
activity, the major distinguishing feature of the two mutants is the additional loss of 
Mdm2:MdmX heterodimerization in Mdm2C462A, which led us to speculate that the Mdm2:MdmX 
heterodimer can facilitate regulation of p53 activity in the absence of Mdm2 E3 ligase activity. 
While preliminary, our data demonstrates a correlation between disruption of Mdm2:MdmX 
interaction and increased binding between p53 and the acetyltransferase p300. Further, this 
increased level of p53:p300 binding correlates with increased levels of p53 acetylation, 
providing a potential mechanism to explain the increased transcription of p53 target genes in the 
absence of Mdm2:MdmX heterodimerization. 
The p53 pathway has been rigorously studied, but as exemplified by the findings in this 
study, in vivo analysis often sheds new light on hypotheses based on in vitro data. The majority 
of existing therapeutics targeting the p53 pathway rely on disruption of Mdm2:p53 interaction to 
reactivate p53, making a comprehensive understanding of Mdm2 regulation of p53 essential for 
the development of anti-cancer drugs targeting the p53 pathway to become a reality (Hoe et al., 
2014). In conjunction with the many existing Mdm2, MdmX, and p53 mutant models, the 
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Mdm2Y487A model proves to be an additional useful tool in elucidating the basic regulatory 
mechanisms of p53 regulation, allowing for even greater depth of study in the future. 
 
Future Directions 
The generation and characterization of the Mdm2Y487A mutation in vivo, in concert with 
insight gleaned from previously developed mouse models, including Mdm2C462A, MdmXC462A, 
and MdmXΔRING, provides strong correlative support to suggest that Mdm2:MdmX heterodimer 
formation is the critical function of the Mdm2 RING finger domain in p53 regulation (Huang et al., 
2011; Itahana et al., 2007; Pant et al., 2011). Although this study has served to further implicate 
heterodimerization between Mdm2 and MdmX as an essential component of p53 regulation, 
and suggests inhibition of p53 acetylation as one mechanism through which Mdm2:MdmX 
heterodimers function, a definitive explanation of the potentially multifaceted function of the 
Mdm2:MdmX heterodimer in the p53 regulatory pathway remains elusive. While initial 
characterization of the Mdm2Y487A mouse has brought to the forefront additional areas to be 
explored in the Mdm2:MdmX:p53 regulatory pathway, through further investigation such as that 
described below, significant insight remains to be parsed out from the existing mouse models to 
improve our understanding of p53 regulation in vivo.  
One mechanism for Mdm2:MdmX heterodimer-mediated regulation of p53 activity, 
proposed here, is the modulation of p53 acetylation. Loss of Mdm2:MdmX heterodimerization in 
MEFs correlated with increased interaction of p53 with the acetyltransferase p300, which 
corresponded to higher levels of acetylated p53. The recently developed p533KR knock-in mouse 
model introduces lysine-to-arginine substitutions at amino acid residues 117, 161, and 162 of 
murine p53 to disrupt p53 acetylation; despite maintaining normal DNA binding properties, 
p533KR fails to promote the transcription of a number of key p53 target genes for cell cycle arrest, 
apoptosis, and senescence in response to stress (Li et al., 2012). The ablation of cell cycle 
arrest, apoptosis, and senescence in the presence of p533KR provides additional data to support 
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the importance of p53 post-translational modifications in the determination of p53 activity. To 
examine the biological significance of the repression of p53 acetylation by Mdm2:MdmX 
heterodimerization in vivo, mice harboring mutations to disrupt both p53 acetylation, as well as 
Mdm2:MdmX interaction (i.e. Mdm2C462A, MdmXC462A or MdmXΔRING) could be generated. 
Disruption of Mdm2:MdmX heterodimerization results in p53-dependent embryonic lethality, 
however, if this lethality is able to be rescued in the p533KR genetic background, it would provide 
critical in vivo evidence to support this mechanism of p53 regulation (Clegg et al., 2012; Huang 
et al., 2011; Itahana et al., 2007; Pant et al., 2011). In the case that disruption of p53 acetylation 
is not sufficient to rescue the aberrant p53 activity and embryonic lethality observed in the 
absence of Mdm2:MdmX heterodimerization, the use of an inducible or hypomorphic mutant 
p53 could allow for further investigation of MEFs to better understand the correlation between 
Mdm2:MdmX heterodimerization, p53 acetylation, and p53 activity.  
A second potential mechanism to explain the apparent necessity of Mdm2:MdmX 
heterodimerization for p53 regulation is based on its role in the subcellular localization of Mdm2, 
MdmX, and p53. While MdmX does not harbor its own NLS or NES, through interaction with 
Mdm2 and p53, MdmX can shuttle between the cytoplasm and nucleus (Li et al., 2002; Marine 
and Jochemsen, 2005). Interestingly, disruption of Mdm2:MdmX interaction as a result of 
Mdm2ΔRING mutation does not affect MdmX localization, although this may simply be the result of 
technical limitations in observing transient nucleo-cytoplasmic shuttling (Pant et al., 2011). 
MdmX localization in the cytoplasm contributes to its function as a negative regulator of p53; 
MdmX:p53 interaction serves to tether p53 in the cytoplasm, which reduces p53 activity 
(Jimenez et al., 1999; Moll et al., 1995; Ohtsubo et al., 2009). Introduction of a nuclear 
localization signal to MdmX in vitro results in decreased levels of cytoplasmic p53, suggesting 
that localization of MdmX to the cytoplasm is functionally relevant for its inhibitory effect on p53 
activity (Ohtsubo et al., 2009). Generation of an MdmX mutant mouse with a functional nuclear 
localization signal sequence would allow us to further understand the role of MdmX subcellular 
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localization in vivo. The development of such a model would provide for experimentation and 
observation of endogenous protein levels to determine whether nuclear MdmX has an inhibitory 
or enhancing effect on p53 activity, potentially due to increased formation of Mdm2:MdmX 
heterodimers, or reduced cytoplasmic tethering of p53, respectively.   
siRNA knockdown of MdmX in WT and Mdm2Y487A/Y487A MEFs correlates with 
stabilization of p53, however, the magnitude of p53 accumulation in Mdm2Y487A/Y487A suggests 
that in addition to increasing p53 activity, simultaneous loss of Mdm2 E3 ligase activity and 
Mdm2:MdmX interaction also results in increased p53 stability (Figure 4-1). Further investigation 
of the effect of Mdm2:MdmX heterodimerization on the transcription and translation of p53 is 
essential in broadening our understanding of p53 stabilization and accumulation. Disruption of 
Mdm2:MdmX heterodimerization via concomitant deletion of MdmX similarly increased p53 
stability and activity in Mdm2Y487A/Y487A MEFs, however, the possibility that this increase in p53 
activity is not solely due to loss of Mdm2:MdmX interaction cannot be overlooked, specifically in 
light of the well characterized role the MdmX p53 binding domain plays in inhibiting p53 
transactivation (Marine and Jochemsen, 2005; Shvarts et al., 1996). To minimize the potentially 
confounding effects of deleting the entire MdmX protein, generation of 
Mdm2Y487A/Y497A;MdmXC462A/C462A or Mdm2Y487A/Y487A;MdmXΔRING/ΔRING double mutants could be 
utilized to better assess the effect of simultaneous loss of Mdm2 E3 ubiquitin ligase activity and 
Mdm2:MdmX interaction. Although the Mdm2C462A mutant disrupts both of these Mdm2 RING 
finger domain functions, it also likely affects Mdm2 RING domain protein structure, and thus the 
development of the Mdm2Y487A/Y487A;MdmXC462A/C462A or Mdm2Y487A/Y487A;MdmXΔRING/ΔRING model 
could provide valuable complementary data.  
Although p53 can be activated via a variety of stimuli, including DNA damage, ribosomal 
stress, and oncogene activation, generally, Mdm2 is considered to act as the “gatekeeper” of 
p53 activity and stabilization in response to each of these types of cellular stress (Bond et al., 
2005; Wade et al., 2010). Loss of Mdm2 E3 ligase activity, as observed in the Mdm2Y487A/Y487A 
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mouse, results in maintained high levels of p53 stabilization and activity following DNA damage 
and ribosomal stress, but it remains to be assessed if oncogene activation would similarly 
stimulate high levels of p53 stabilization and activity in the absence of robust Mdm2 E3 ligase 
activity. The c-Myc oncogene is well established to activate p53 through the ARF-Mdm2 
pathway; the use of Eµ-Myc transgenic mice provides an effective model for B-cell lymphoma 
(Adams et al., 1985; Eischen et al., 1999). Deletion of p53 results in decreased time to onset of 
B-cell lymphomas in Eµ-Myc transgenic mice; furthermore, disruption of ribosomal 
protein:Mdm2 binding accelerates Eµ-Myc lymphomagenesis, pointing to the importance of 
RP:Mdm2 interaction in regulating c-Myc activation of p53 (Hsu et al., 1995; Macias et al., 2010). 
It remains unknown if loss of Mdm2 E3 ubiquitin ligase activity would serve a protective or 
deleterious role in Eµ-Myc lymphomagenesis, however, preliminary data suggests that loss of 
Mdm2 E3 ligase function does not extend the survival of Eµ-Myc mice, and in fact may even 
result in earlier mortality (Figure 4-2). To directly assess if loss of Mdm2 E3 ligase activity 
results in increased p53 stabilization and activity following oncogene activation, p53 levels in 
normal tissue and tumors of Mdm2+/+;Eµ-Myc and Mdm2Y487A/Y487A;Eµ-Myc mice should be 
assessed; additionally, overexpression of Myc in WT and Mdm2Y487A/Y487A MEFs provides a 
useful platform for evaluating the effect of oncogene activation of p53 in the presence and 
absence of Mdm2 E3 ubiquitin ligase activity, respectively. Of note, Mdm2Y487A/Y487A;Eµ-Myc 
mice were generated at low rates; detailed assessment and analysis of additional 
Mdm2Y487A/Y487A;Eµ-Myc intercrosses could reveal a role for aberrant activation of p53 in 
embryogenesis as a result of the combined effect of loss of Mdm2 E3 ligase activity and the Eµ-
Myc transgene.  
It is evident that much remains to be clarified in the Mdm2:MdmX:p53 regulatory 
pathway, however, the insight provided by the current study on basic regulatory dynamics may 
aid in understanding differential efficacy and mechanisms of action in existing therapeutics, and 
in directing the focus of future pharmacological studies targeting the p53 pathway. In contrast 
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with previous beliefs, the Mdm2Y487A model indicates that under unstressed basal conditions, 
disruption of Mdm2 E3 ligase function alone is not sufficient to increase p53 activity. Thus, 
although drug targeting of enzymatic activity is generally more efficient than disruption of 
protein-protein interactions, isolated use of compounds that disrupt Mdm2 E3 ligase function 
may not effectively induce p53 activity in vivo (Kitagaki et al., 2008; Makley and Gestwicki, 
2013). The high level of p53 activation observed in the presence of Mdm2Y487A following γ 
irradiation indicates that the use of compounds disrupting Mdm2:p53 interaction in combination 
with other chemotherapies or radiation therapy may be an efficient mechanism for reactivating 
p53. The knowledge gained through the advent of in vivo models of the Mdm2:MdmX:p53 
pathway exemplifies the continuing innovation in resources and techniques, and provides 
promise for improved understanding of this pathway under physiological and disease relevant 
conditions, which will ideally lead to successful therapeutic targeting of p53 in the future. 
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Figure 4-1. Knockdown of MdmX Increases p53 Stability. 
Mdm2+/+ (WT) and Mdm2Y487A/Y487A (487/487) MEFs were transfected with control siRNA 
(siCtrl) or MdmX siRNA (siMdmX4, siMdmX5, or siMdmX6) for 48 hours.  Cell lysates were 
collected and Mdm2, MdmX, and p53 levels were analyzed by western blot. Actin was used 
as a loading control. 
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Figure 4-2. Mdm2Y487A Does Not Increase Survival Following Oncogene Activation. 
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Mdm2+/+; MycT/+, Mdm2Y487A/+;MycT/+, and Mdm2Y487A/Y487A;MycT/+ male and female mice were 
observed weekly for activity and viability. Kaplan-Meier survival curve is shown. 
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